Prestige Consumer Healthcare Inc. - Quarter Report: 2007 September (Form 10-Q)
U.
S. SECURITIES AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
10-Q
[
X ]
|
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE
ACT OF 1934
|
For
the quarterly period ended September 30,
2007
or
[ ]
|
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE
ACT OF 1934
|
For
the transition period from ____ to _____
Commission
File Number: 001-32433
PRESTIGE
BRANDS HOLDINGS, INC.
(Exact
name of Registrant as specified in its charter)
Delaware
|
20-1297589
|
|
(State
or other jurisdiction of
incorporation
or organization)
|
(I.R.S.
Employer Identification No.)
|
90
North Broadway
Irvington,
New York 10533
|
(Address
of Principal Executive Offices, including zip code)
|
(914)
524-6810
|
(Registrant’s
telephone number, including area
code)
|
Indicate
by check mark whether the Registrant (1) has filed all reports required to
be
filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the
preceding 12 months (or for such shorter period that the Registrant was required
to file such reports), and (2) has been subject to such filing requirements
for
the past 90 days. Yes x No o
Indicate
by check mark whether the Registrant is a large accelerated filer, an
accelerated filer, or a non-accelerated filer. See definition of
“accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange
Act. (Check one):
Large accelerated filer o | Accelerated filer x | Non-accelerated filer o |
Indicate
by check mark whether the Registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act).
Yes o
No
x
As
of
October 31, 2007, there were 50,003,321 shares of common stock
outstanding.
Prestige
Brands Holdings, Inc.
Form
10-Q
Index
PART
I.
|
FINANCIAL
INFORMATION
|
|
Item
1.
|
Consolidated
Financial Statements
|
|
Consolidated
Statements of Operations – three months ended September 30, 2007 and
2006 and six months ended September 30, 2007 and 2006
(unaudited)
|
2
|
|
|
||
Consolidated
Balance Sheets – September 30, 2007 and March 31, 2007
(unaudited)
|
3
|
|
Consolidated
Statement of Changes in Stockholders’ Equity and Comprehensive
Income – six months ended September 30, 2007
(unaudited)
|
4
|
|
|
|
|
Consolidated
Statements of Cash Flows – three months ended September 30, 2007 and
2006 and six months ended September 30, 2007 and 2006
(unaudited)
|
5
|
|
|
|
|
Notes
to Unaudited Consolidated Financial Statements
|
6
|
|
Item
2.
|
Management’s
Discussion and Analysis of Financial Condition and
Results of Operations
|
24
|
Item
3.
|
Quantitative
and Qualitative Disclosure About Market Risk
|
41
|
Item
4.
|
Controls
and Procedures
|
41
|
PART
II.
|
OTHER
INFORMATION
|
|
Item
1.
|
Legal
Proceedings
|
42
|
Item
1A.
|
Risk
Factors
|
43
|
Item
2.
|
Unregistered
Sales of Equity Securities and Use of Proceeds
|
43
|
Item
4.
|
Submission
of Matters to a Vote of Security Holders
|
43
|
Item
6.
|
Exhibits
|
44
|
|
Signatures
|
45
|
-1-
PART
I
|
FINANCIAL
INFORMATION
|
Item
1.
|
FINANCIAL
STATEMENTS
|
Prestige
Brands Holdings, Inc.
Consolidated
Statements of Operations
(Unaudited)
Three
Months
Ended
September 30
|
Six
Months
Ended
September 30
|
|||||||||||||||
(In
thousands, except per share data)
|
2007
|
2006
|
2007
|
2006
|
||||||||||||
Revenues
|
||||||||||||||||
Net
sales
|
$ |
86,840
|
$ |
84,033
|
$ |
164,881
|
$ |
159,600
|
||||||||
Other
revenues
|
497
|
518
|
1,067
|
874
|
||||||||||||
Total
revenues
|
87,337
|
84,551
|
165,948
|
160,474
|
||||||||||||
Cost
of Sales
|
||||||||||||||||
Costs
of sales
|
42,770
|
41,259
|
80,092
|
77,584
|
||||||||||||
Gross
profit
|
44,567
|
43,292
|
85,856
|
82,890
|
||||||||||||
Operating
Expenses
|
||||||||||||||||
Advertising
and promotion
|
11,017
|
9,455
|
18,803
|
16,857
|
||||||||||||
General
and administrative
|
10,184
|
7,259
|
17,830
|
13,693
|
||||||||||||
Depreciation
|
129
|
219
|
253
|
439
|
||||||||||||
Amortization
of intangible assets
|
2,627
|
2,193
|
5,254
|
4,386
|
||||||||||||
Total
operating expenses
|
23,957
|
19,126
|
42,140
|
35,375
|
||||||||||||
Operating
income
|
20,610
|
24,166
|
43,716
|
47,515
|
||||||||||||
Other
income (expense)
|
||||||||||||||||
Interest
income
|
173
|
403
|
360
|
588
|
||||||||||||
Interest
expense
|
(9,768 | ) | (10,146 | ) | (19,642 | ) | (20,123 | ) | ||||||||
Total
other income (expense)
|
(9,595 | ) | (9,743 | ) | (19,282 | ) | (19,535 | ) | ||||||||
Income
before provision for
income taxes
|
11,015
|
14,423
|
24,434
|
27,980
|
||||||||||||
Provision
for income taxes
|
4,186
|
5,639
|
9,285
|
10,940
|
||||||||||||
Net
income
|
$ |
6,829
|
$ |
8,784
|
$ |
15,149
|
$ |
17,040
|
||||||||
Basic
earnings per share
|
$ |
0.14
|
$ |
0.18
|
$ |
0.30
|
$ |
0.35
|
||||||||
Diluted
earnings per share
|
$ |
0.14
|
$ |
0.18
|
$ |
0.30
|
$ |
0.34
|
||||||||
Weighted
average shares outstanding:
Basic
|
49,710
|
49,451
|
49,686
|
49,389
|
||||||||||||
Diluted
|
50,046
|
49,994
|
50,042
|
49,991
|
See
accompanying notes.
-2-
Prestige
Brands Holdings, Inc.
Consolidated
Balance Sheets
(Unaudited)
(In
thousands)
Assets
|
September
30, 2007
|
March
31, 2007
|
||||||
Current
assets
|
||||||||
Cash
and cash equivalents
|
$ |
8,799
|
$ |
13,758
|
||||
Accounts
receivable
|
46,512
|
35,167
|
||||||
Inventories
|
27,783
|
30,173
|
||||||
Deferred
income tax assets
|
3,337
|
2,735
|
||||||
Prepaid
expenses and other current assets
|
3,628
|
1,935
|
||||||
Total
current assets
|
90,059
|
83,768
|
||||||
Property
and equipment
|
1,391
|
1,449
|
||||||
Goodwill
|
308,915
|
310,947
|
||||||
Intangible
assets
|
651,903
|
657,157
|
||||||
Other
long-term assets
|
8,310
|
10,095
|
||||||
Total
Assets
|
$ |
1,060,578
|
$ |
1,063,416
|
||||
Liabilities
and Stockholders’ Equity
|
||||||||
Current
liabilities
|
||||||||
Accounts
payable
|
$ |
21,318
|
$ |
19,303
|
||||
Accrued
interest payable
|
7,556
|
7,552
|
||||||
Other
accrued liabilities
|
12,771
|
10,505
|
||||||
Current
portion of long-term debt
|
3,550
|
3,550
|
||||||
Total
current liabilities
|
45,195
|
40,910
|
||||||
Long-term
debt
|
433,563
|
459,800
|
||||||
Other
long-term liabilities
|
2,801
|
2,801
|
||||||
Deferred
income tax liabilities
|
117,609
|
114,571
|
||||||
Total
Liabilities
|
599,168
|
618,082
|
||||||
Commitments
and Contingencies – Note 13
|
||||||||
Stockholders’
Equity
|
||||||||
Preferred
stock - $0.01 par value
|
||||||||
Authorized
–
5,000
shares
|
||||||||
Issued
and outstanding –
None
|
--
|
--
|
||||||
Common
stock - $0.01 par value
|
||||||||
Authorized
–
250,000
shares
|
||||||||
Issued
–
50,060
shares
|
501
|
501
|
||||||
Additional
paid-in capital
|
380,371
|
379,225
|
||||||
Treasury
stock, at cost – 57 shares at September 30, 2007
and
55 shares at March 31, 2007
|
(44 | ) | (40 | ) | ||||
Accumulated
other comprehensive income
|
98
|
313
|
||||||
Retained
earnings
|
80,484
|
65,335
|
||||||
Total
stockholders’ equity
|
461,410
|
445,334
|
||||||
Total
Liabilities and Stockholders’ Equity
|
$ |
1,060,578
|
$ |
1,063,416
|
See
accompanying notes.
-3-
Prestige
Brands Holdings, Inc.
Consolidated
Statement of Changes in Stockholders’ Equity
and
Comprehensive Income
Six
Months Ended September 30, 2007
(Unaudited)
Common
Stock
Par
Shares
Value
|
Additional
Paid-in
Capital
|
Treasury
Stock
Shares
Amount
|
Accumulated
Other
Comprehensive
Income
|
Retained
Earnings
|
Totals
|
|||||||||||||||||||||||||||
(In
thousands)
|
||||||||||||||||||||||||||||||||
Balances
- March 31, 2007
|
50,060
|
$ |
501
|
$ |
379,225
|
55
|
$ | (40 | ) | $ |
313
|
$ |
65,335
|
$ |
445,334
|
|||||||||||||||||
Stock-based
compensation
|
--
|
--
|
1,146
|
--
|
--
|
--
|
--
|
1,146
|
||||||||||||||||||||||||
Purchase
of common stock for treasury
|
--
|
--
|
--
|
2
|
(4 | ) |
--
|
--
|
(4 | ) | ||||||||||||||||||||||
Components
of comprehensive income:
|
||||||||||||||||||||||||||||||||
Net
income
|
--
|
--
|
--
|
--
|
--
|
--
|
15,149
|
15,149
|
||||||||||||||||||||||||
Amortization
of interest rate caps reclassified into earnings, net of income tax
expense of $139
|
--
|
--
|
--
|
--
|
--
|
218
|
--
|
218
|
||||||||||||||||||||||||
Unrealized
loss on interest rate caps, net of income tax benefit of
$277
|
--
|
--
|
--
|
--
|
--
|
(433 | ) |
--
|
(433 | ) | ||||||||||||||||||||||
Total
comprehensive income
|
--
|
--
|
--
|
--
|
--
|
--
|
--
|
14,934
|
||||||||||||||||||||||||
Balances
– September 30, 2007
|
50,060
|
$ |
501
|
$ |
380,371
|
57
|
$ | (44 | ) | $ |
98
|
$ |
80,484
|
$ |
461,410
|
See
accompanying notes.
-4-
Prestige
Brands Holdings, Inc.
Consolidated
Statements of Cash Flows
(Unaudited)
Six
Months Ended September 30
|
||||||||
(In
thousands)
|
2007
|
2006
|
||||||
Operating
Activities
|
||||||||
Net
income
|
$ |
15,149
|
$ |
17,040
|
||||
Adjustments
to reconcile net income to net cash provided by operating
activities:
|
||||||||
Depreciation
and amortization
|
5,507
|
4,825
|
||||||
Deferred
income taxes
|
4,622
|
6,197
|
||||||
Amortization
of deferred financing costs
|
1,561
|
1,609
|
||||||
Stock-based
compensation
|
1,146
|
224
|
||||||
Changes
in operating assets and liabilities
|
||||||||
Accounts
receivable
|
(11,345 | ) |
2,595
|
|||||
Inventories
|
2,390
|
5,202
|
||||||
Prepaid
expenses and other current assets
|
(1,692 | ) | (1,047 | ) | ||||
Accounts
payable
|
1,884
|
4,494
|
||||||
Income
taxes payable
|
--
|
(1,731 | ) | |||||
Accrued
liabilities
|
2,270
|
3,326
|
||||||
Net
cash provided by operating activities
|
21,492
|
42,734
|
||||||
Investing
Activities
|
||||||||
Purchases
of equipment
|
(194 | ) | (313 | ) | ||||
Purchase
of business
|
(16 | ) | (31,242 | ) | ||||
Net
cash used for investing activities
|
(210 | ) | (31,555 | ) | ||||
Financing
Activities
|
||||||||
Repayment
of long-term debt
|
(26,237 | ) | (8,865 | ) | ||||
Purchase
of common stock for treasury
|
(4 | ) | (6 | ) | ||||
Net
cash used for financing activities
|
(26,241 | ) | (8,871 | ) | ||||
Increase
(decrease) in cash
|
(4,959 | ) |
2,308
|
|||||
Cash
- beginning of period
|
13,758
|
8,200
|
||||||
Cash
- end of period
|
$ |
8,799
|
$ |
10,508
|
||||
Interest
paid
|
$ |
18,078
|
$ |
18,306
|
||||
Income
taxes paid
|
$ |
5,664
|
$ |
6,287
|
See
accompanying notes.
|
-5-
Prestige
Brands Holdings, Inc.
Notes
to Consolidated Financial Statements
(Unaudited)
1.
|
Business
and Basis of Presentation
|
Nature
of Business
|
Prestige
Brands Holdings, Inc. (referred to herein as the “Company” which reference
shall, unless the context requires otherwise, be deemed to refer to Prestige
Brands Holdings, Inc. and all of its direct or indirect wholly-owned
subsidiaries on a consolidated basis) is engaged in the marketing, sales and
distribution of over-the-counter healthcare, personal care and household
cleaning brands to mass merchandisers, drug stores, supermarkets and club stores
primarily in the United States, Canada and certain international
markets. Prestige Brands Holdings, Inc. is a holding company with no
assets or operations and is also the parent guarantor of the senior secured
credit facility and the senior subordinated notes more fully described in Note
8
to the consolidated financial statements.
Basis
of Presentation
|
The
unaudited consolidated financial statements presented herein have been prepared
in accordance with generally accepted accounting principles for interim
financial reporting and with the instructions to Form 10-Q and Article 10 of
Regulation S-X. Accordingly, they do not include all of the
information and footnotes required by United States generally accepted
accounting principles (“GAAP”) for complete financial statements. All
significant intercompany transactions and balances have been
eliminated. In the opinion of management, the financial statements
include all adjustments, consisting of normal recurring adjustments that are
considered necessary for a fair presentation of the Company’s consolidated
financial position, results of operations and cash flows for the interim
periods. Operating results for the three and six month periods ended
September 30, 2007 are not necessarily indicative of results that may be
expected for the year ending March 31, 2008. This financial
information should be read in conjunction with the Company’s financial
statements and notes thereto included in the Company’s Annual Report on Form
10-K for the year ended March 31, 2007.
Use
of Estimates
The
preparation of financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the reported amounts
of
assets and liabilities and disclosure of contingent assets and liabilities
at
the date of the financial statements, as well as the reported amounts of
revenues and expenses during the reporting period. Although these
estimates are based on the Company’s knowledge of current events and actions
that the Company may undertake in the future, actual results could differ
materially from those estimates. As discussed below, the Company’s
most significant estimates include those made in connection with the valuation
of intangible assets, sales returns and allowances, trade promotional allowances
and inventory obsolescence.
Cash
and Cash Equivalents
The
Company considers all short-term deposits and investments with original
maturities of three months or less to be cash
equivalents. Substantially all of the Company’s cash is held by one
bank located in Wyoming. The Company does not believe that, as a
result of this concentration, it is subject to any unusual financial risk beyond
the normal risk associated with commercial banking relationships.
Accounts
Receivable
The
Company extends non-interest bearing trade credit to its customers in the
ordinary course of business. The Company maintains an allowance for
doubtful accounts receivable based upon historical collection experience and
expected collectibility of the accounts receivable. In an effort to
reduce credit risk, the Company (i) has established credit limits for all of
its
customer relationships, (ii) performs ongoing credit evaluations of customers’
financial condition, (iii) monitors the payment history and aging of customers’
receivables, and (iv) monitors open orders against an individual customer’s
outstanding receivable balance.
-6-
Inventories
Inventories
are stated at the lower of cost or fair value, where cost is determined by
using
the first-in, first-out method. The Company provides an allowance for
slow moving and obsolete inventory, whereby it reduces inventories for the
diminution of value, resulting from product obsolescence, damage or other issues
affecting marketability, equal to the difference between the cost of the
inventory and its estimated market value. Factors utilized in the
determination of estimated market value include (i) current sales data and
historical return rates, (ii) estimates of future demand, (iii) competitive
pricing pressures, (iv) new product introductions, (v) product expiration dates,
and (vi) component and packaging obsolescence.
Property
and Equipment
Property
and equipment are stated at cost and are depreciated using the straight-line
method based on the following estimated useful lives:
Years
|
|
Machinery
|
5
|
Computer
equipment
|
3
|
Furniture
and fixtures
|
7
|
Leasehold
improvements
|
5
|
Expenditures
for maintenance and repairs are charged to expense as incurred. When
an asset is sold or otherwise disposed of, the cost and associated accumulated
depreciation are removed from the accounts and the resulting gain or loss is
recognized in the consolidated statement of operations.
Property
and equipment are reviewed for impairment whenever events or changes in
circumstances indicate that the carrying amount of such assets may not be
recoverable. An impairment loss is recognized if the carrying amount
of the asset exceeds its fair value.
Goodwill
The
excess of the purchase price over the fair market value of assets acquired
and
liabilities assumed in purchase business combinations is classified as
goodwill. In accordance with Financial Accounting Standards Board
(“FASB”) Statement of Financial Accounting Standards (“Statement”) No. 142,
“Goodwill and Other Intangible Assets,” the Company does not amortize goodwill,
but performs impairment tests of the carrying value at least
annually. The Company tests goodwill for impairment at the “brand”
level which is one level below the operating segment level.
Intangible
Assets
Intangible
assets, which are composed primarily of trademarks, are stated at cost less
accumulated amortization. For intangible assets with finite lives,
amortization is computed on the straight-line method over estimated useful
lives
ranging from five to 20 years.
Indefinite
lived intangible assets are tested for impairment at least annually, while
intangible assets with finite lives are reviewed for impairment whenever events
or changes in circumstances indicate that the carrying amount of such assets
may
not be recoverable. An impairment loss is recognized if the carrying
amount of the asset exceeds its fair value.
Deferred
Financing Costs
The
Company has incurred debt issuance costs in connection with its long-term
debt. These costs are capitalized as deferred financing costs and
amortized using the straight-line method, which approximates the effective
interest method, over the term of the related debt.
-7-
Revenue
Recognition
Revenues
are recognized in accordance with Securities and Exchange Commission (“SEC”)
Staff Accounting Bulletin 104, “Revenue Recognition,” when the following
criteria are met: (1) persuasive evidence of an arrangement exists; (2) the
product has been shipped and the customer takes ownership and assumes risk
of
loss; (3) the selling price is fixed or determinable; and (4) collection of
the
resulting receivable is reasonably assured. The Company has
determined that the transfer of risk of loss occurs when product is received
by
the customer and, accordingly, recognizes revenue at that
time. Provision is made for estimated discounts related to customer
payment terms and estimated product returns at the time of sale based on the
Company’s historical experience.
As
is customary in
the consumer products industry, the
Company
participates
in the promotional programs of its customers to enhance the sale of its
products. The cost of these promotional programs varies based
on the actual number of units sold during a finite period of time. The
Company estimates the cost of such promotional programs at their inception
based
on historical experience and current market conditions and reduces sales by
such
estimates. These
promotional
programs consist of direct to consumer incentives such as coupons and
temporary price reductions, as well as incentives to the Company’s customers,
such as slotting fees and cooperative advertising. Estimates of the
costs of these promotional programs are based on (i) historical sales
experience, (ii) the current offering, (iii) forecasted data, (iv) current
market conditions, and (v) communication with customer purchasing/marketing
personnel. At the completion of the promotional program, the
estimated amounts are adjusted to actual results.
Due
to
the nature of the consumer products industry, the Company is required to
estimate future product returns. Accordingly, the Company records an
estimate of product returns concurrent with recording sales which is made after
analyzing (i) historical return rates, (ii) current economic trends, (iii)
changes in customer demand, (iv) product acceptance, (v) seasonality of the
Company’s product offerings, and (vi) the impact of changes in product
formulation, packaging and advertising.
Costs
of Sales
Costs
of
sales include product costs, warehousing costs, inbound and outbound shipping
costs, and handling and storage costs. Shipping, warehousing and
handling costs were $6.6 million and $6.5 million for the three month periods
ended September 30, 2007 and 2006, respectively, and $12.2 million for each
of
the six month periods ended September 30, 2007 and 2006,
respectively.
Advertising
and Promotion Costs
Advertising
and promotion costs are expensed as incurred. Slotting fees
associated with products are recognized as a reduction of
sales. Under slotting arrangements, the retailers allow the Company’s
products to be placed on the stores’ shelves in exchange for such
fees. Direct reimbursements of advertising costs are reflected as a
reduction of advertising costs in the period earned.
Stock-based
Compensation
During
fiscal 2006,
the Company adopted FASB, Statement No. 123(R), “Share-Based Payment”
(“Statement No. 123(R)”) with the grants of restricted stock and options to
purchase common stock to employees and directors in accordance with the
provisions of the Company’s 2005 Long-Term Equity Incentive Plan (the
“Plan”). Statement No. 123(R) requires the Company to measure the
cost of services to be rendered based on the grant-date fair value of the equity
award. Compensation expense is to be recognized over the period an
employee is required to provide service in exchange for the award, generally
referred to as the requisite service period, and is included as a component
of
general and administrative expenses. The Company recorded stock-based
compensation costs of $685,000 and $1.1 million during the three and six month
periods ended September 30, 2007, respectively. During the three and
six month periods ended September 30, 2006, the Company recorded stock-based
compensation costs of $233,000 and $224,000, respectively. During the
three month period ended June 30, 2006, the Company recorded a net stock-based
compensation credit of $9,000 due to the reversal of stock-based compensation
costs in the amount of $142,000 associated with the departure of a former member
of management.
Income
Taxes
Income
taxes are recorded in accordance with the provisions of FASB Statement No.
109,
“Accounting for Income Taxes” (“Statement No. 109”). Pursuant to
Statement No. 109, deferred tax assets and liabilities are
-8-
determined
based on the differences between the financial reporting and tax bases of assets
and liabilities using the enacted tax rates and laws that will be in effect
when
the differences are expected to reverse. A valuation allowance is
established when necessary to reduce deferred tax assets to the amounts expected
to be realized.
In
June
2006, the FASB issued FASB Interpretation No. 48, “Accounting for Uncertainty in
Income Taxes--an interpretation of FASB Statement 109” (“FIN 48”), which
clarifies the accounting for uncertainty in income taxes recognized in a
company’s financial statements in accordance with Statement No.
109. FIN 48 prescribes a recognition threshold and measurement
attributes for the financial statement recognition and measurement of a tax
position taken or expected to be taken in a tax return. As a result,
the Company has applied a more-likely-than-not recognition threshold for all
tax
uncertainties. FIN 48 allows the recognition of only those tax
benefits that have a greater than 50% likelihood of being sustained upon
examination by the various taxing authorities. The adoption of FIN
48, effective April 1, 2007, did not result in a cumulative effect adjustment
to
the opening balance of retained earnings or adjustment to any of the components
of assets, liabilities or equity in the consolidated balance sheet.
The
Company is subject to federal and state taxation in the US, as well as in
various foreign jurisdictions. The Company remains subject to
examination by tax authorities for years after 2003.
The
Company classifies penalties and interest related to unrecognized tax benefits
as income tax expense in the Statement of Operations.
Derivative
Instruments
FASB
Statement No. 133, “Accounting for Derivative Instruments and Hedging
Activities” (“Statement No. 133”), requires companies to recognize derivative
instruments as either assets or liabilities in the balance sheet at fair
value. The accounting for changes in the fair value of a derivative
instrument depends on whether it has been designated and qualifies as part
of a
hedging relationship and further, on the type of hedging
relationship. For those derivative instruments that are designated
and qualify as hedging instruments, a company must designate the hedging
instrument, based upon the exposure being hedged, as a fair value hedge, a
cash
flow hedge or a hedge of a net investment in a foreign operation.
The
Company has designated its derivative financial instruments as cash flow hedges
because they hedge exposure to variability in expected future cash flows that
are attributable to interest rate risk. For these hedges, the
effective portion of the gain or loss on the derivative instrument is reported
as a component of other comprehensive income (loss) and reclassified into
earnings in the same line item associated with the forecasted transaction in
the
same period or periods during which the hedged transaction affects earnings.
Any
ineffective portion of the gain or loss on the derivative instruments is
recorded in results of operations immediately.
Earnings
Per Share
Basic
earnings per share is calculated based on income available to common
stockholders and the weighted-average number of shares outstanding during the
reporting period. Diluted earnings per share is calculated based on
income available to common stockholders and the weighted-average number of
common and potential common shares outstanding during the reporting
period. Potential common shares, composed of the incremental common
shares issuable upon the exercise of stock options, stock appreciation rights
and unvested restricted shares, are included in the earnings per share
calculation to the extent that they are dilutive.
Fair
Value of Financial Instruments
The
carrying value of cash, accounts receivable and accounts payable at both
September 30, 2007 and March 31, 2007 approximates fair value due to the
short-term nature of these instruments. The carrying value of
long-term debt at both September 30, 2007 and March 31, 2007 approximates fair
value based on interest rates for instruments with similar terms and
maturities.
Recently
Issued Accounting Standards
In
February 2007, the FASB issued SFAS No. 159, “The Fair Value Option for
Financial Assets and Financial Liabilities - Including an amendment of FASB
Statement No. 115” (“Statement No. 159”). Statement No. 159 permits
companies to choose to measure certain financial instruments and certain other
items at fair value.
-9-
Unrealized
gains and losses on items for which the fair value option has been elected
will
be recognized in earnings at each subsequent reporting
date. Statement No. 159 is effective for the Company’s interim
financial statements issued after April 1, 2008. The Company is
evaluating the impact that the adoption of Statement No. 159 will have on its
consolidated financial statements.
In
September 2006, the FASB issued SFAS No. 157, “Fair Value Measurements”
(“Statement No. 157”) to address inconsistencies in the definition and
determination of fair value pursuant to GAAP. Statement No. 157
provides a single definition of fair value, establishes a framework for
measuring fair value in GAAP and expands disclosures about fair value
measurements in an effort to increase comparability related to the recognition
of market-based assets and liabilities and their impact on
earnings. Statement No. 157 is effective for the Company’s interim
financial statements issued after April 1, 2008. The Company is
evaluating the impact that the adoption of Statement No. 157 will have on its
consolidated financial statements.
Management
has reviewed and continues to monitor the actions of the various financial
and
regulatory reporting agencies and is currently not aware of any other
pronouncement that could have a material impact on the
Company’s consolidated financial position, results of operations or cash
flows.
Accounts
Receivable
|
Accounts
receivable consist of the following (in thousands):
September
30,
2007
|
March
31,
2007
|
|||||||
Accounts
receivable
|
$ |
48,679
|
$ |
35,274
|
||||
Other
receivables
|
1,286
|
1,681
|
||||||
49,965
|
36,955
|
|||||||
Less
allowances for discounts, returns and
uncollectible
accounts
|
(3,453 | ) | (1,788 | ) | ||||
$ |
46,512
|
$ |
35,167
|
Inventories
|
Inventories
consist of the following (in thousands):
September
30,
2007
|
March
31,
2007
|
|||||||
Packaging
and raw materials
|
$ |
2,281
|
$ |
2,842
|
||||
Finished
goods
|
25,502
|
27,331
|
||||||
$ |
27,783
|
$ |
30,173
|
Inventories
are shown net of allowances for obsolete and slow moving inventory of $1.3
million and $1.8 million at September 30, 2007 and March 31, 2007,
respectively.
-10-
|
4.
|
Property
and Equipment
|
Property
and equipment consist of the following (in thousands):
September 30,
2007
|
March
31,
2007
|
|||||||
Machinery
|
$ |
1,397
|
$ |
1,480
|
||||
Computer
equipment
|
477
|
566
|
||||||
Furniture
and fixtures
|
205
|
247
|
||||||
Leasehold
improvements
|
319
|
372
|
||||||
2,398
|
2,665
|
|||||||
Accumulated
depreciation
|
(1,007 | ) | (1,216 | ) | ||||
$ |
1,391
|
$ |
1,449
|
5.
|
Goodwill
|
A
reconciliation of the activity affecting goodwill by operating segment is as
follows (in thousands):
Over-the-Counter
Healthcare
|
Household
Cleaning
|
Personal
Care
|
Consolidated
|
|||||||||||||
Balance
– March 31, 2007
|
$ |
235,647
|
$ |
72,549
|
$ |
2,751
|
$ |
310,947
|
||||||||
Acquisition
purchase price adjustments
|
(2,032 | ) |
--
|
--
|
(2,032 | ) | ||||||||||
Balance
– September 30, 2007
|
$ |
233,615
|
$ |
72,549
|
$ |
2,751
|
$ |
308,915
|
6.
|
Intangible
Assets
|
A
reconciliation of the activity affecting intangible assets is as follows (in
thousands):
Indefinite
Lived
Trademarks
|
Finite
Lived
Trademarks
|
Non
Compete
Agreement
|
Totals
|
|||||||||||||
Carrying
Amounts
|
||||||||||||||||
Balance
– March 31, 2007
|
$ |
544,963
|
$ |
139,470
|
$ |
196
|
$ |
684,629
|
||||||||
Additions
|
--
|
--
|
--
|
--
|
||||||||||||
Balance
– September 30, 2007
|
$ |
544,963
|
$ |
139,470
|
$ |
196
|
$ |
684,629
|
||||||||
Accumulated
Amortization
|
||||||||||||||||
Balance
– March 31, 2007
|
$ |
--
|
$ |
27,375
|
$ |
97
|
$ |
27,472
|
||||||||
Additions
|
--
|
5,232
|
22
|
5,254
|
||||||||||||
Balance
– September 30, 2007
|
$ |
--
|
$ |
32,607
|
$ |
119
|
$ |
32,726
|
-11-
At
September 30, 2007, intangible assets are expected to be amortized over a period
of five to 30 years as follows (in thousands):
Year
Ending September 30
|
||||
2008
|
$ |
10,507
|
||
2009
|
9,799
|
|||
2010
|
9,071
|
|||
2011
|
9,071
|
|||
2012
|
9,071
|
|||
Thereafter
|
59,421
|
|||
$ |
106,940
|
7.
|
Other
Accrued Liabilities
|
Other
accrued liabilities consist of the following (in thousands):
|
September
30,
2007
|
March
31,
2007
|
||||||
|
||||||||
Accrued
marketing costs
|
$ |
7,820
|
$ |
5,687
|
||||
Accrued
payroll
|
3,100
|
3,721
|
||||||
Accrued
commissions
|
357
|
335
|
||||||
Other
|
1,494
|
762
|
||||||
|
$ |
12,771
|
$ |
10,505
|
-12-
8.
|
Long-Term
Debt
|
Long-term
debt consists of the following (in thousands):
September
30,
2007
|
March
31,
2007
|
|||||||
Senior
revolving credit facility (“Revolving Credit Facility”), which expires on
April 6, 2009 and is available for maximum borrowings of up to $60.0
million. The Revolving Credit Facility bears interest at the
Company’s option at either the prime rate plus a variable margin or LIBOR
plus a variable margin. The variable margins range from 0.75%
to 2.50% and at September 30, 2007, the interest rate on the Revolving
Credit Facility was 8.75% per annum. The Company is also
required to pay a variable commitment fee on the unused portion of
the
Revolving Credit Facility. At September 30, 2007, the
commitment fee was 0.50% of the unused line. The Revolving
Credit Facility is collateralized by substantially all of the Company’s
assets.
|
$ |
--
|
$ |
--
|
||||
Senior
secured term loan facility (“Tranche B Term Loan Facility” and together
with the Revolving Credit Facility, the “Senior Credit Facility”) that
bears interest at the Company’s option at either the prime rate plus a
margin of 1.25% or LIBOR plus a margin of 2.25%. At September
30,
2007, the average interest rate on the Tranche B Term Loan Facility
was 7.74%. Principal payments of $887,500 plus accrued interest
are payable quarterly. At September 30, 2007, the Company may
borrow up to a maximum amount of $200.0 million under the Tranche
B Term
Loan Facility. Current amounts outstanding under the Tranche B
Term Loan Facility mature on April 6, 2011, while any additional
amounts
borrowed will mature on October 6, 2011. The Tranche B Term
Loan Facility is collateralized by substantially all of the Company’s
assets.
|
311,113
|
337,350
|
||||||
Senior
Subordinated Notes that bear interest at 9.25% which is payable on
April
15th
and
October 15th
of each
year. The Senior Subordinated Notes mature on April 15, 2012;
however, the Company may redeem some or all of the Senior Subordinated
Notes on or prior to April 15, 2008 at a redemption price equal to
100%
plus a make-whole premium, and after April 15, 2008, at redemption
prices
set forth in the Indenture governing the Senior Subordinated
Notes. The Senior Subordinated Notes are unconditionally
guaranteed by Prestige Brands Holdings, Inc. and its domestic wholly-owned
subsidiaries other than Prestige Brands, Inc., the issuer. Each
of these guarantees is joint and several. There are no
significant restrictions on the ability of any of the guarantors
to obtain
funds from their subsidiaries.
|
126,000
|
126,000
|
||||||
437,113
|
463,350
|
|||||||
Current
portion of long-term debt
|
(3,550 | ) | (3,550 | ) | ||||
$ |
433,563
|
$ |
459,800
|
Effective
as of December 19, 2006: (i) a Second Supplemental Indenture (“Second
Supplemental Indenture”), and (ii) a Guaranty Supplement (“Indenture Guaranty
Supplement”) were entered into with the trustee for the holders
-13-
of
the
Senior Subordinated Notes. The Second Supplemental Indenture
supplements and amends the Indenture, dated as of April 6, 2004, as supplemented
on October 6, 2004 (“Indenture”). Pursuant to the terms of the Second
Supplemental Indenture and the Indenture Guaranty Supplement, the Company agreed
to guaranty all of the obligations of Prestige Brands, Inc., an indirect
wholly-owned subsidiary of the Company (“PBI”), set forth in the Indenture
governing PBI’s Senior Subordinated Notes. The Second Supplemental
Indenture also amended the covenant requiring Prestige Brands International,
LLC
(“Prestige Brands International”), an indirect wholly-owned subsidiary of the
Company, to file periodic reports with the SEC pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934, as amended (“Exchange
Act”). So long as the Company or any other guarantor is required to
file periodic reports under Section 13 or 15(d) of the Exchange Act that are
substantially the same as the periodic reports that Prestige Brands
International would otherwise be required to file with the SEC pursuant to
the
Indenture, Prestige Brands International is not required to file such
reports.
Also
effective as of December 19, 2006, a Joinder Agreement (“Joinder Agreement”) and
a Guaranty Supplement (“Credit Agreement Guaranty Supplement”) were entered into
with the administrative agent for the lenders under the Senior Credit
Facility. Pursuant to the terms of the Joinder Agreement and the
Credit Agreement Guaranty Supplement, the Company agreed to become a party
to
the Pledge and Security Agreement (“Security Agreement”) and the Guaranty
(“Credit Agreement Guaranty”), each dated as of April 6, 2004, by PBI and
certain of its affiliates in favor of the lenders. The Security
Agreement and the Credit Agreement Guaranty secure the performance by PBI of
its
obligations under the Credit Agreement, dated as of April 6, 2004, as amended
(“Credit Agreement”), by granting security interests to PBI’s lenders in
collateral owned by the Company and certain of its subsidiaries and providing
guaranties of such obligations by certain of PBI’s affiliates.
The
Senior Credit Facility contains various financial covenants, including
provisions that require the Company to maintain certain leverage ratios,
interest coverage ratios and fixed charge coverage ratios. The Senior
Credit Facility and the Senior Subordinated Notes also contain provisions that
restrict the Company from undertaking specified corporate actions, such as
asset
dispositions, acquisitions, dividend payments, repurchase of common shares
outstanding, changes of control, incurrence of indebtedness, creation of liens,
making of loans and transactions with affiliates. Additionally, the
Senior Credit Facility and the Senior Subordinated Notes contain cross-default
provisions whereby a default pursuant to the terms and conditions of either
indebtedness will cause a default on the remaining indebtedness. At
September 30, 2007, the Company was in compliance with its applicable financial
and other covenants under the Senior Credit Facility and the
Indenture.
Future
principal payments required in accordance with the terms of the Senior Credit
Facility and the Senior Subordinated Notes are as follows (in
thousands):
Year
Ending September 30
|
||||
2008
|
$ |
3,550
|
||
2009
|
3,550
|
|||
2010
|
3,550
|
|||
2011
|
300,463
|
|||
2012
|
126,000
|
|||
$ |
437,113
|
In
an
effort to mitigate the impact of changing interest rates, the Company entered
into interest rate cap agreements with various financial
institutions. In June 2004, the Company purchased a 5% interest rate
cap with a notional amount of $20.0 million which expired in June
2006. In March 2005, the Company purchased interest rate cap
agreements with a total notional amount of $180.0 million and cap rates ranging
from 3.25% to 3.75%. On May 31, 2006, an interest rate cap agreement
with a notional amount of $50.0 million and a 3.25% cap rate
expired. Additionally, an interest rate cap agreement with a notional
amount of $80.0 million and a 3.50% cap rate expired on May 30,
2007. The remaining agreement, with a notional amount of $50.0
million and a cap rate of 3.75%, terminates on May 30, 2008. The
Company is accounting for the interest rate cap agreements as cash flow
hedges. The fair values of the interest rate cap agreements, which
are included in other long-term assets, were $486,000 and $1.2 million at
September 30, 2007 and March 31,
2007,
respectively.
-14-
9.
|
Stockholders’
Equity
|
The
Company is authorized to issue 250.0 million shares of common stock, $0.01
par
value per share, and 5.0 million shares of preferred stock, $0.01 par value
per
share. The Board of Directors may direct the issuance of the undesignated
preferred stock in one or more series and determine preferences, privileges
and
restrictions thereof.
Each
share of common stock has the right to one vote on all matters submitted to
a
vote of stockholders. The holders of common stock are also entitled
to receive dividends whenever funds are legally available and when declared
by
the Board of Directors, subject to prior rights of holders of all classes of
stock outstanding having priority rights as to dividends. No
dividends have been declared or paid on the Company’s common stock through
September 30, 2007.
10.
|
Earnings
Per Share
|
The
following table sets forth the computation of basic and diluted earnings per
share (in thousands):
Three
Months Ended
September
30
|
Six
Months Ended
September
30
|
|||||||||||||||
2007
|
2006
|
2007
|
2006
|
|||||||||||||
Numerator
|
||||||||||||||||
Net
income
|
$ |
6,829
|
$ |
8,784
|
$ |
15,149
|
$ |
17,040
|
||||||||
Denominator
|
||||||||||||||||
Denominator
for basic earnings per share – weighted average shares
|
49,710
|
49,451
|
49,686
|
49,389
|
||||||||||||
Dilutive
effect of unvested restricted common stock
|
336
|
543
|
356
|
602
|
||||||||||||
Denominator
for diluted earnings
per
share
|
50,046
|
49,994
|
50,042
|
49,991
|
||||||||||||
Earnings
per Common Share:
|
||||||||||||||||
Basic
|
$ |
0.14
|
$ |
0.18
|
$ |
0.30
|
$ |
0.35
|
||||||||
Diluted
|
$ |
0.14
|
$ |
0.18
|
$ |
0.30
|
$ |
0.34
|
At
September 30, 2007, 243,000 shares of restricted stock issued to management
and
employees prior to the Company’s initial public offering are unvested and
excluded from the calculation of basic earnings per share; however, such shares
are included in the calculation of diluted earnings per share. At
September 30, 2007, 160,000 shares of restricted stock granted to management,
directors and employees, subject only to time vesting requirements, have been
excluded from basic earnings per share; however, such shares are included in
the
calculation of diluted earnings per share. Additionally, 378,000
shares of restricted stock granted to management and employees, as well as
16,000 stock appreciation rights have been excluded from the calculation of
both
basic and diluted earnings per share since vesting of such shares is subject
to
contingencies, while options to purchase 255,000 shares of common stock have
been excluded from diluted earnings per shares because their inclusion would
be
anti-dilutive.
At
September 30, 2006, 522,000 shares of restricted stock issued to management
and
employees prior to the Company’s initial public offering were unvested and
excluded from the calculation of basic earnings per share; however, such shares
are included in the calculation of diluted earnings per
share. Additionally, at September 30, 2006, 278,000 shares of
restricted stock granted to management and employees have been excluded from
the
calculation of both basic and diluted earnings per share since vesting of such
shares is subject to contingencies.
-15-
11.
|
Share-Based
Compensation
|
In
connection with the Company’s initial public offering, the Board of Directors
adopted the Plan which provides for the grant, to a maximum of 5.0
million shares, of stock options, restricted stock units, deferred stock units
and other equity-based awards. Directors, officers and other
employees of the Company and its subsidiaries, as well as others performing
services for the Company, are eligible for grants under the Plan. The
Company believes that such awards better align the interests of its employees
with those of its stockholders.
During
2006, the Company adopted Statement No. 123(R) with the initial grants of
restricted stock and options to purchase common stock to employees and directors
in accordance with the provisions of the Plan. During the six month
period ended September 30, 2007, the Company recorded compensation costs and
related tax benefits of $1.1 million and $418,000, respectively, while during
the six month period ended September 30, 2006, the Company recorded compensation
costs and related tax benefits of $225,000 and $88,000,
respectively.
Restricted
Shares
Restricted
shares granted under the Plan generally vest in 3 years, contingent on
attainment of Company performance goals, including both revenue and earnings
per
share growth targets, or time vesting, as determined by the Compensation
Committee of the Board of Directors. Certain restricted share awards
provide for accelerated vesting if there is a change of control. The
fair value of nonvested restricted shares is determined as the closing price
of
the Company’s common stock on the day preceding the grant date. The
weighted-average grant-date fair value of restricted shares granted during
2007
was $12.52.
A
summary
of the Company’s restricted shares granted under the Plan is presented
below:
Restricted
Shares
|
Shares
(000)
|
Weighted-Average
Grant-Date
Fair
Value
|
||||||
Nonvested
at March 31, 2006
|
198.0
|
$ |
12.32
|
|||||
Granted
|
156.5
|
9.83
|
||||||
Vested
|
(13.1 | ) |
10.67
|
|||||
Forfeited
|
(39.0 | ) |
12.82
|
|||||
Nonvested
at September 30, 2006
|
302.4
|
$ |
11.04
|
|||||
Nonvested
at March 31, 2007
|
294.4
|
$ |
11.05
|
|||||
Granted
|
292.0
|
12.52
|
||||||
Vested
|
(24.8 | ) |
10.09
|
|||||
Forfeited
|
(23.2 | ) |
11.39
|
|||||
Nonvested
at September 30, 2007
|
538.4
|
$ |
11.88
|
-16-
Options
The
Plan
provides that the exercise price of the option granted shall be no less than
the
fair market value of the Company’s common stock on the date the option is
granted. Options granted have a term of no greater than 10 years from
the date of grant and vest in accordance with a schedule determined at the
time
the option is granted, generally 3 years.
The
fair
value of each option award is estimated on the date of grant using the
Black-Scholes Option Pricing Model (“Black-Scholes Model”) that uses the
assumptions noted in the following table. Expected volatilities are
based on the historical volatility of the Company’s common stock and other
factors, including the historical volatilities of comparable
companies. The Company uses appropriate historical data, as well as
current data, to estimate option exercise and employee termination
behaviors. Employees that are expected to exhibit similar exercise or
termination behaviors are grouped together for the purposes of
valuation. The expected terms of the options granted are derived from
management’s estimates and information derived from the public filings of
companies similar to the Company and represent the period of time that options
granted are expected to be outstanding. The risk-free rate represents
the yield on U.S. Treasury bonds with a maturity equal to the expected term
of
the granted option. The weighted-average grant-date fair value of the
options granted during the six month period ended September 30, 2007 was
$5.30. There were no options granted during 2006.
2007
|
2006
|
|||||||
Expected
volatility
|
33.2 | % |
--
|
|||||
Expected
dividends
|
--
|
--
|
||||||
Expected
term in years
|
6.0
|
--
|
||||||
Risk-free
rate
|
4.5 | % |
--
|
A
summary
of option activity under the Plan is as follows:
Options
|
Shares
(000)
|
Weighted-Average
Exercise
Price
|
Weighted-
Average
Remaining
Contractual
Term
|
|||||||||
Outstanding
at March 31, 2006
|
61.8
|
$ |
12.95
|
4.3
|
||||||||
Granted
|
--
|
--
|
--
|
|||||||||
Exercised
|
--
|
--
|
--
|
|||||||||
Forfeited
or expired
|
(61.8 | ) |
12.95
|
--
|
||||||||
Outstanding
at September 30, 2006
|
--
|
$ |
--
|
--
|
||||||||
Outstanding
at March 31, 2007
|
--
|
$ |
--
|
--
|
||||||||
Granted
|
255.1
|
12.86
|
10.0
|
|||||||||
Exercised
|
--
|
--
|
--
|
|||||||||
Forfeited
or expired
|
--
|
--
|
--
|
|||||||||
Outstanding
at September 30, 2007
|
255.1
|
$ |
12.86
|
10.0
|
||||||||
Exercisable
at September 30, 2007
|
--
|
$ |
--
|
--
|
Stock
Appreciation Rights (“SARS”)
The
Plan
provides that the issuance price of a SAR shall be no less than the market
price
of the Company’s common stock on the date the SAR is granted. SARS
may be granted with a term of no greater than 10 years from the date of grant
and will vest in accordance with a schedule determined at the time the SAR
is
granted, generally 3 years. The Board of Directors, in its sole
discretion, may settle the Company’s obligation to the executive in shares of
the Company’s common stock, cash, other securities of the Company or any
combination thereof. The weighted-average grant date fair value of
the SARS granted during the six month period ended September 30, 2006 was
$3.68. There were no SARS granted during the six month period ended
September 30,
-17-
2007. The
fair value of each SAR award was estimated on the date of grant using the
Black-Scholes Model using the assumptions noted in the following
table.
2007
|
2006
|
|||||||
Expected
volatility
|
--
|
50.0 | % | |||||
Expected
dividends
|
--
|
--
|
||||||
Expected
term in years
|
--
|
2.8
|
||||||
Risk-free
rate
|
--
|
5.0 | % |
A
summary
of SARS activity under the Plan is as follows:
SARS
|
Shares
(000)
|
Grant
Date
Stock
Price
|
Weighted-
Average
Remaining
Contractual
Term
|
|||||||||
Outstanding
at March 31, 2006
|
--
|
$ |
--
|
--
|
||||||||
Granted
|
16.1
|
9.97
|
2.75
|
|||||||||
Forfeited
or expired
|
--
|
--
|
--
|
|||||||||
Outstanding
at September 30, 2006
|
16.1
|
$ |
9.97
|
2.5
|
||||||||
Exercisable
at September 30, 2006
|
--
|
$ |
--
|
--
|
||||||||
Outstanding
at March 31, 2007
|
16.1
|
$ |
9.97
|
2.00
|
||||||||
Granted
|
--
|
--
|
--
|
|||||||||
Forfeited
or expired
|
--
|
--
|
--
|
|||||||||
Outstanding
at September 30, 2007
|
16.1
|
$ |
9.97
|
1.50
|
||||||||
Exercisable
at September 30, 2007
|
--
|
$ |
--
|
--
|
At
September 30, 2007 and March 31, 2007, there were $4.9 million and $1.4 million,
respectively, of unrecognized compensation costs related to nonvested
share-based compensation arrangements under the Plan based on management’s
estimate of the shares that will ultimately vest. The Company expects
to recognize such costs over the next 3.0 years. However, certain of
the restricted shares vest upon the attainment of Company performance goals
and
if such goals are not met, no compensation costs would ultimately be recognized
and any previously recognized compensation cost would be reversed. At
September 30, 2007, there were 4.1 million shares available for issuance under
the Plan.
12.
|
Income
Taxes
|
Income
taxes are recorded in the Company’s quarterly financial statements based on the
Company’s estimated annual effective income tax rate. The effective
tax rates used in the calculation of income taxes were 38.0% and 39.1% for
the
periods ended September 30, 2007 and 2006, respectively. The
reduction in the income tax rates results from the implementation of initiatives
to obtain operational, as well as tax, efficiencies during the fiscal year
ended
March 31, 2007.
At
September 30, 2007, Medtech Products Inc., a wholly-owned subsidiary of the
Company, had a net operating loss carryforward of approximately $2.6 million
which may be used to offset future taxable income of the consolidated group
and
which begins to expire in 2020. The net operating loss carryforward
is subject to an annual limitation as to usage under Internal Revenue Code
Section 382 of approximately $240,000.
-18-
Commitments
and Contingencies
|
The
legal
proceedings in which we are involved have been disclosed previously in our
Annual Report on Form 10-K for the fiscal year ended March 31, 2007, our
Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2007 and
our
Current Report on Form 8-K filed with the SEC on October 24,
2007. The following disclosure contains recent developments in our
pending legal proceedings and should be read in conjunction with the legal
proceedings disclosure contained in Part I, Item 3 of our Annual Report on
Form
10-K for the fiscal year ended March 31, 2007, Part II, Item 1 of our Quarterly
Report on Form 10-Q for the fiscal quarter ended June 30, 2007 and our Current
Report on Form 8-K filed with the SEC on October 24, 2007.
Securities
Class Action Litigation
On
September 4, 2007, the United States District Court for the Southern District
of
New York issued an Order certifying a class consisting of all persons who
purchased the common stock of the Company pursuant to, or traceable to, the
Company’s initial public offering on or about February 9, 2005 through November
15, 2005 and were damaged thereby. The Company’s management continues
to believe that the remaining claims in the case are legally deficient and
that
it has meritorious defenses to the claims that remain. The Company
intends to vigorously defend against the claims remaining in the case;
however, the Company cannot reasonably estimate the potential range of loss,
if
any.
OraSure
Technologies Arbitration
At
the
end of August 2007, the Company and OraSure Technologies, Inc. (“OraSure”)
participated in an arbitration hearing at which each party presented its
case to
the arbitration panel. On October 22, 2007, the Company received
notification from the arbitrators that they had issued a Partial Final Award
(the “Award”) in the pending arbitration with OraSure. The
arbitrators acknowledged that there was a technical breach of the non-compete
clause in the Distribution Agreement between the parties but OraSure’s proof of
damages was speculative and not supported by credible
evidence. Therefore, the arbitrators awarded nominal damages to
OraSure in the amount of One Dollar ($1.00). In addition, the
arbitrators awarded to OraSure counsel fees and arbitrator compensation in
an
amount to be determined pursuant to further proceedings. The Company
will vigorously contest the award of fees to OraSure as the Company believes
that OraSure should only be entitled to a modest award in light of the
arbitrators’ rejection of OraSure’s asserted damages and claims beyond the One
Dollar ($1.00) nominal award.
The
arbitration panel also dismissed with prejudice OraSure’s remaining claims for
breach of the Distribution Agreement, OraSure’s request for injunctive relief
and the Company’s counterclaims, respectively. Furthermore, the
arbitrators confirmed the Company's position that the Distribution Agreement
will terminate on December 31, 2007. The Company does not expect any
interruptions in supply of its Compound W Freeze Off® branded cryosurgical wart
remover as it transitions to a new supplier after December 31,
2007.
DenTek
Oral Care, Inc. Litigation
In
April
2007, the Company filed a lawsuit in the U.S. District Court in the Southern
District of New York against DenTek Oral Care, Inc. (“DenTek”) alleging (i)
infringement of intellectual property associated with The Doctor’s®
NightGuardTM
dental protector
which is used for the protection of teeth from
nighttime teeth grinding; and (ii) the violation of unfair competition and
consumer protection laws. On October 4, 2007, the Company filed a
Second Amended Complaint in which it named Kelly M. Kaplan, Raymond Duane and
C.D.S. Associates, Inc. as additional defendants in the action against DenTek
and added other claims to the previously filed complaint. Ms. Kaplan
and Mr. Duane were formerly employed by the Company and C.D.S. Associates,
Inc.
is a corporation controlled by Mr. Duane. In the Second Amended
Complaint, the Company has alleged patent, trademark and copyright infringement,
unfair competition, unjust enrichment, violation of New York’s Consumer
Protection Act, breach of contract, tortuous interference with contractual
and
business relations, civil conspiracy and trade secret
misappropriation. On October 19, 2007, the Company filed a motion for
preliminary injunction with the Court in which the Company has asked the Court
to enjoin the defendants from (i) continuing to improperly use the Company’s
trade secrets; (ii) continuing to breach any contractual agreements with the
Company; and (iii) marketing and selling any dental protector products or other
products in which Ray Duane or Kelly Kaplan has had any involvement or provided
any assistance to DenTek. A hearing date for the motion for
preliminary injunction has not yet been set by the Court. Discovery
requests have been served by the parties and discovery is ongoing.
-19-
In
addition to the matters described above, the Company is involved from time
to time in other routine legal matters and other claims incidental to its
business. The Company reviews outstanding claims and proceedings
internally and with external counsel as necessary to assess probability and
amount of potential loss. These assessments are re-evaluated at each
reporting period and as new information becomes available to determine whether
a
reserve should be established or if any existing reserve should be
adjusted. The actual cost of resolving a claim or proceeding
ultimately may be substantially different than the amount of the recorded
reserve. In addition, because it is not permissible under GAAP to
establish a litigation reserve until the loss is both probable and estimable,
in
some cases there may be insufficient time to establish a reserve prior to the
actual incurrence of the loss (upon verdict and judgment at trial, for example,
or in the case of a quickly negotiated settlement). The Company
believes the resolution of routine matters and other incidental claims, taking
into account reserves and insurance, will not have a material adverse effect
on
its business, financial condition or results from operations.
Lease
Commitments
The
Company has operating leases for office facilities and equipment in New York,
New Jersey and Wyoming, which expire at various dates through 2011.
The
following summarizes future minimum lease payments for the Company’s operating
leases (in thousands):
Facilities
|
Equipment
|
Total
|
||||||||||
Year
Ending September 30,
|
||||||||||||
2008
|
$ |
650
|
$ |
122
|
$ |
772
|
||||||
2009
|
362
|
98
|
460
|
|||||||||
2010
|
--
|
67
|
67
|
|||||||||
2011
|
--
|
4
|
4
|
|||||||||
$ |
1,012
|
$ |
291
|
$ |
1,303
|
Rent
expense for the three month periods ended September 30, 2007 and 2006 was
$145,000 and $136,000, respectively; while during the six month periods ended
September 30, 2007 and 2006, rent expense was $298,000 and $275,000,
respectively.
Concentrations
of Risk
|
The
Company’s sales are concentrated in the areas of over-the-counter healthcare,
household cleaning and personal care products. The Company sells its
products to mass merchandisers, food and drug accounts, and dollar and club
stores. During the three and six month periods ended September 30,
2007 approximately 56.4% and 56.5%, respectively, of the Company’s total sales
were derived from its four major brands, while during the three and six month
periods ended September 30, 2006, approximately 61.1% and 60.2%, respectively,
of the Company’s total sales were derived from these four major
brands. During the three and six month periods ended September 30,
2007, approximately 22.8% and 23.8%, respectively, of the Company’s sales were
made to one customer, while during the three and six month periods ended
September 30, 2006, 24.1% and 24.6% of sales were to this customer. At
September 30, 2007, approximately 19.5% of accounts receivable were owed by
the
same customer.
The
Company manages product distribution in the continental United States through
a
main distribution center in St. Louis, Missouri. A serious
disruption, such as a flood or fire, to the main distribution center could
damage the Company’s inventories and could materially impair the Company’s
ability to distribute its products to customers in a timely manner or at a
reasonable cost. The Company could incur significantly higher costs
and experience longer lead times associated with the distribution of its
products to its customers during the time that it takes the Company to reopen
or
replace its distribution center. As a result, any such disruption
could have a material adverse affect on the Company’s sales and
profitability.
-20-
The
Company has relationships with over 40 third-party manufacturers. Of
those, the top 10 manufacturers produced items that accounted for approximately
79% of the Company’s gross sales during the six months ended September 30,
2007. The Company does not have long-term contracts with 4 of these
manufacturers and certain manufacturers of various smaller brands, which
collectively, represented approximately 35% of the Company’s gross sales for
2007. The lack of manufacturing agreements for these products exposes
the Company to the risk that a manufacturer could stop producing the Company’s
products at any time, for any reason or fail to provide the Company with the
level of products the Company needs to meet its customers’
demands. Without adequate supplies of merchandise to sell to the
Company’s customers, sales would decrease materially and the Company’s business
would suffer.
15.
|
Business
Segments
|
Segment
information has been prepared in accordance with FASB Statement No. 131,
“Disclosures about Segments of an Enterprise and Related
Information.” The Company’s operating and reportable segments consist
of (i) Over-the-Counter Healthcare, (ii) Household Cleaning and (iii) Personal
Care.
There
were no inter-segment sales or transfers during any of the periods
presented. The Company evaluates the performance of its operating
segments and allocates resources to them based primarily on contribution
margin.
The
table
below summarizes information about the Company’s operating and reportable
segments (in thousands).
Three
Months Ended September 30, 2007
|
||||||||||||||||
Over-the-Counter
|
Household
|
Personal
|
||||||||||||||
Healthcare
|
Cleaning
|
Care
|
Consolidated
|
|||||||||||||
Net
sales
|
$ |
50,003
|
30,925
|
$ |
5,912
|
$ |
86,840
|
|||||||||
Other
revenues
|
--
|
497
|
--
|
497
|
||||||||||||
Total
revenues
|
50,003
|
31,422
|
5,912
|
87,337
|
||||||||||||
Cost
of sales
|
19,688
|
19,587
|
3,495
|
42,770
|
||||||||||||
Gross
profit
|
30,315
|
11,835
|
2,417
|
44,567
|
||||||||||||
Advertising
and promotion
|
8,154
|
2,575
|
288
|
11,017
|
||||||||||||
Contribution
margin
|
$ |
22,161
|
$ |
9,260
|
$ |
2,129
|
33,550
|
|||||||||
Other
operating expenses
|
12,940
|
|||||||||||||||
Operating
income
|
20,610
|
|||||||||||||||
Other
(income) expense
|
9,595
|
|||||||||||||||
Provision
for income taxes
|
4,186
|
|||||||||||||||
Net
income
|
$ |
6,829
|
-21-
Six
Months Ended September 30, 2007
|
||||||||||||||||
Over-the-Counter
|
Household
|
Personal
|
||||||||||||||
Healthcare
|
Cleaning
|
Care
|
Consolidated
|
|||||||||||||
Net
sales
|
$ |
92,429
|
$ |
60,270
|
$ |
12,182
|
$ |
164,881
|
||||||||
Other
revenues
|
--
|
1,039
|
28
|
1,067
|
||||||||||||
Total
revenues
|
92,429
|
61,309
|
12,210
|
165,948
|
||||||||||||
Cost
of sales
|
35,074
|
37,980
|
7,038
|
80,092
|
||||||||||||
Gross
profit
|
57,355
|
23,329
|
5,172
|
85,856
|
||||||||||||
Advertising
and promotion
|
14,035
|
4,203
|
565
|
18,803
|
||||||||||||
Contribution
margin
|
$ |
43,320
|
$ |
19,126
|
$ |
4,607
|
67,053
|
|||||||||
Other
operating expenses
|
23,337
|
|||||||||||||||
Operating
income
|
43,716
|
|||||||||||||||
Other
(income) expense
|
19,282
|
|||||||||||||||
Provision
for income taxes
|
9,285
|
|||||||||||||||
Net
income
|
$ |
15,149
|
Three
Months Ended September 30, 2006
|
||||||||||||||||
Over-the-Counter
Healthcare
|
Household
Cleaning
|
Personal
Care
|
Consolidated
|
|||||||||||||
Net
sales
|
$ |
46,255
|
$ |
30,732
|
$ |
7,046
|
$ |
84,033
|
||||||||
Other
revenues
|
--
|
518
|
--
|
518
|
||||||||||||
Total
revenues
|
46,255
|
31,250
|
7,046
|
84,551
|
||||||||||||
Cost
of sales
|
18,001
|
18,941
|
4,317
|
41,259
|
||||||||||||
Gross
profit
|
28,254
|
12,309
|
2,729
|
43,292
|
||||||||||||
Advertising
and promotion
|
7,058
|
2,020
|
377
|
9,455
|
||||||||||||
Contribution
margin
|
$ |
21,196
|
$ |
10,289
|
$ |
2,352
|
33,837
|
|||||||||
Other
operating expenses
|
9,671
|
|||||||||||||||
Operating
income
|
24,166
|
|||||||||||||||
Other
(income) expense
|
9,743
|
|||||||||||||||
Provision
for income taxes
|
5,639
|
|||||||||||||||
Net
income
|
$ |
8,784
|
-22-
Six
Months Ended September 30, 2006
|
||||||||||||||||
Over-the-Counter
Healthcare
|
Household
Cleaning
|
Personal
Care
|
Consolidated
|
|||||||||||||
Net
sales
|
$ |
85,853
|
$ |
60,470
|
$ |
13,277
|
$ |
159,600
|
||||||||
Other
revenues
|
--
|
874
|
--
|
874
|
||||||||||||
Total
revenues
|
85,853
|
61,344
|
13,277
|
160,474
|
||||||||||||
Cost
of sales
|
32,398
|
37,095
|
8,091
|
77,584
|
||||||||||||
Gross
profit
|
53,455
|
24,249
|
5,186
|
82,890
|
||||||||||||
Advertising
and promotion
|
12,483
|
3,710
|
664
|
16,857
|
||||||||||||
Contribution
margin
|
$ |
40,972
|
$ |
20,539
|
$ |
4,522
|
66,033
|
|||||||||
Other
operating expenses
|
18,518
|
|||||||||||||||
Operating
income
|
47,515
|
|||||||||||||||
Other
(income) expense
|
19,535
|
|||||||||||||||
Provision
for income taxes
|
10,940
|
|||||||||||||||
Net
income
|
$ |
17,040
|
During
the three month periods ended September 30, 2007 and 2006, approximately 96.6%
and 96.4%, respectively, of the Company’s sales were made to customers in the
United States and Canada while during the six month periods ended September
30,
2007 and 2006, approximately 95.7% and 96.2%, respectively, of sales were made
to customers in the US and Canada. At September 30, 2007,
substantially all of the Company’s long-term assets were located in the United
States of America and have been allocated to the operating segments as
follows:
Over-the-Counter
|
Household
|
Personal
|
||||||||||||||
Healthcare
|
Cleaning
|
Care
|
Consolidated
|
|||||||||||||
Goodwill
|
$ |
233,615
|
$ |
72,549
|
$ |
2,751
|
$ |
308,915
|
||||||||
Intangible
assets
|
||||||||||||||||
Indefinite
lived
|
374,070
|
170,893
|
--
|
544,963
|
||||||||||||
Finite
lived
|
90,986
|
15
|
15,939
|
106,940
|
||||||||||||
465,056
|
170,908
|
15,939
|
651,903
|
|||||||||||||
$ |
698,671
|
$ |
243,457
|
$ |
18,690
|
$ |
960,818
|
-23-
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
|
The
following discussion of our financial condition and results of operations should
be read together with the consolidated financial statements and the related
notes included in our Annual Report on Form 10-K for the fiscal year ended
March
31, 2007. This discussion and analysis may contain forward-looking
statements that involve certain risks, assumptions and
uncertainties. Future results could differ materially from the
discussion that follows for many reasons, including the factors described in
Part I, Item 1A., “Risk Factors” in our Annual Report on Form 10-K for the
fiscal year ended March 31, 2007, as well as those described in future reports
filed with the SEC. See also “Cautionary Statements Regarding Forward
Looking Statements” on page 40 of this Quarterly Report on Form
10-Q.
General
We
are
engaged in the marketing, sales and distribution of brand name over-the-counter
healthcare, household cleaning and personal care products to mass merchandisers,
drug stores, supermarkets and club stores primarily in the United States and
Canada. We operate in niche segments of these categories where we can
use the strength of our brands, our established retail distribution network,
a
low-cost operating model and our experienced management team as a competitive
advantage to grow our presence in these categories and, as a result, grow our
sales and profits.
We
have
grown our brand portfolio by acquiring strong and well-recognized brands from
larger consumer products and pharmaceutical companies, as well as other brands
from smaller private companies. While the brands we have purchased
from larger consumer products and pharmaceutical companies have long histories
of support and brand development, we believe that at the time we acquired them
they were considered “non-core” by their previous owners and did not benefit
from the focus of senior level management or strong marketing
support. We believe that the brands we have purchased from smaller
private companies have been constrained by the limited resources of their prior
owners. After acquiring a brand, we seek to increase its sales,
market share and distribution in both existing and new channels. We
pursue this growth through increased spending on advertising and promotion,
new
marketing strategies, improved packaging and formulations and innovative new
products.
In
October 2005, we completed the acquisition of the “Chore Boy®” brand of cleaning
pads and sponges. The purchase price of this acquisition was $22.6
million, including direct costs of $400,000. We purchased the Chore
Boy brand with funds generated from operations.
In
November 2005, we completed the acquisition of Dental Concepts LLC, a marketer
of therapeutic oral care products sold under “The Doctor’s®”
brand. The purchase price of the ownership interests was
approximately $30.2 million, including fees and expenses of the acquisition
of
$1.3 million. We financed the acquisition price through the
utilization of our Revolving Credit Facility in the amount of $30.0 million
and
cash on hand.
In
September 2006, we completed the acquisition of Wartner USA B.V., a privately
held Netherlands limited liability company, which owned the intellectual
property associated with the “Wartner®”
brand of
over-the-counter wart treatment products. The purchase price of this
acquisition was $31.2 million, inclusive of direct costs of the acquisition
of
$216,000. We purchased the Wartner brand with funds generated from
operations and the assumption of approximately $5.0 million of contingent
payments to the former owner of the Wartner brand.
-24-
|
Three
Month Period Ended September 30, 2007 compared to
the
|
|
Three
Month Period Ended September 30,
2006
|
Revenues
2007
Revenues
|
%
|
2006
Revenues
|
%
|
Increase
(Decrease)
|
%
|
|||||||||||||||||||
OTC
Healthcare
|
$ |
50,003
|
57.2
|
$ |
46,255
|
54.7
|
$ |
3,748
|
8.1
|
|||||||||||||||
Household
Cleaning
|
31,422
|
36.0
|
31,250
|
37.0
|
172
|
0.6
|
||||||||||||||||||
Personal
Care
|
5,912
|
6.8
|
7,046
|
8.3
|
(1,134 | ) | (16.1 | ) | ||||||||||||||||
$ |
87,337
|
100.0
|
$ |
84,551
|
100.0
|
$ |
2,786
|
3.3
|
Revenues
for the three month period ended September 30, 2007 increased $2.8 million,
or
3.3%, versus the comparable period in 2006, primarily as a result of the
acquisition of the Wartner brand in September of 2006. Excluding the
impact of the Wartner acquisition, revenues increased 0.6% versus the comparable
period in 2006. Revenues to customers outside of North America, which
represents 3.4% of total revenues, decreased 18% in 2007 versus the comparable
period in 2006.
During
the three month period ended September 30, 2007, the Company increased its
allowance for returns by $1.1 million as a result of the voluntary withdrawal
from the marketplace of two medicated pediatric cough and cold products marketed
under the Little Remedies brand. This action was part of an industry
wide voluntary withdrawal of these items pending the final results of an FDA
safety and efficacy review. Excluding the impact of the withdrawal,
total revenues for the Company would have been $88.4 million, or 4.6% greater
than the comparable period in 2006, and up 1.8% excluding the Wartner
acquisition.
Over-the-Counter
Healthcare Segment
Revenues
of the
Over-the-Counter Healthcare segment increased by $3.7 million, or 8.1%, for
2007
versus the comparable period in 2006. The increase was primarily due
to the acquisition of the Wartner brand in September 2006 and the launch of
MurineTM
EarigateTM,
a new product
that helps prevent earwax build-up with its patented reverse spray
technology. Excluding the impact of the Wartner acquisition, revenues
increased by 3.2% for
the
period. In addition to Murine, Clear eyes®, New Skin and Dermoplast®
revenues increased for the period. Clear eyes and New Skin revenue
increased as a result of increased consumption, and Dermoplast revenue increased
as a result of strong shipments to wholesale distributors of the institutional
size item. These revenue increases were partially offset by an
increase in the allowance for returns of $1.1 million in connection with the
voluntary withdrawal of Little Remedies medicated pediatric cough and cold
products, lower shipments to the trade of Chloraseptic cough and cold products
in advance of the flu season, softer consumption of Compound
W
Freeze-off® as a result of a contraction in the cryogenic sub-segment of the
wart removal category and lower consumption of The Doctor’s®
NightGuardTM
dental protector
as a result of increased competition in the bruxism
category.
Household
Cleaning Segment
Revenues
of the Household Cleaning segment were substantially unchanged at $31.4 million,
increasing only 0.6% during the quarter versus the comparable period in
2006. Revenues of the Comet® brand were
essentially flat for the period and declines in Spic and Span were offset by
increased revenue of Chore Boy. Revenue of Comet Mildew SprayGel,
which was launched in the last quarter of fiscal 2007, was mostly offset by
weak
factory sales of Comet powder due to inventory reductions taken at a
key
mass merchandiser customer. The decline in Spic and Span’s revenue
reflected a decline in consumer sales. The increase of Chore Boy
sales were a result of strong shipments to small grocer wholesale accounts;
however, consumption declined during the period.
Personal
Care Segment
Revenues
of the Personal Care segment declined $1.1 million or 16.1% for the period
versus the comparable period in 2006. All major brands in this
segment, except for Prell, experienced revenue declines during the
period. The decrease in revenue of Cutex®
and
Denorex® were
a result of declining consumption. Prell’s revenue increased
slightly for the period, in line with consumption.
-25-
Gross
Profit
2007
Gross
Profit
|
%
|
2006
Gross
Profit
|
%
|
Increase
(Decrease)
|
%
|
|||||||||||||||||||
OTC
Healthcare
|
$ |
30,315
|
60.6
|
$ |
28,254
|
61.1
|
$ |
2,061
|
7.3
|
|||||||||||||||
Household
Cleaning
|
11,835
|
37.7
|
12,309
|
39.4
|
(474 | ) | (3.9 | ) | ||||||||||||||||
Personal
Care
|
2,417
|
40.9
|
2,729
|
38.7
|
(312 | ) | (11.4 | ) | ||||||||||||||||
$ |
44,567
|
51.0
|
$ |
43,292
|
51.2
|
$ |
1,275
|
2.9
|
Gross
profit for 2007 increased by $1.3 million, or 2.9%, versus the comparable period
in 2006. As a percent of total revenue, gross profit decreased
slightly from 51.2% in 2006 to 51.0% during 2007. The decrease in
gross profit as a percent of revenues is a result of a $1.1 million increase
in
the allowance for returns in connection with the voluntary withdrawal of the
two
Little Remedies medicated products discussed above and related obsolescence
charges of $800,000.
Over-the-Counter
Healthcare Segment
Gross
profit of the Over-the-Counter Healthcare segment increased $2.1 million, or
7.3%, for 2007 versus the comparable period in 2006. As a percent of
OTC revenue, gross profit decreased from 61.1% for 2006 to 60.6% during
2007. The decrease in gross profit as a percent of revenues is a
result of the $1.1 million increase in the allowance for returns for the
voluntary withdrawal of the Little Remedies medicated products discussed above
and related obsolescence charges of $800,000.
Household
Cleaning Segment
Gross
profit of the Household Cleaning segment decreased by $474,000, or 3.9%, for
2007 versus the comparable period in 2006. As a percent of household
cleaning revenue, gross profit decreased from 39.4% for 2006 to 37.7% during
2007. The decrease in gross profit percentage is primarily a result
of higher product costs partially offset by lower distribution
costs.
Personal
Care Segment
Gross
profit of the Personal Care segment decreased $312,000, or 11.4%, for 2007
versus the comparable period in 2006. As a percent of personal care
revenue, gross profit increased from 38.7% for 2006 to 40.9% during
2007. The increase in gross profit percentage was primarily a result
of the favorable product mix toward the higher margin shampoo
businesses.
Contribution
Margin
2007
Contribution
Margin
|
%
|
2006
Contribution
Margin
|
%
|
Increase
(Decrease)
|
%
|
|||||||||||||||||||
OTC
Healthcare
|
$ |
22,161
|
44.3
|
$ |
21,196
|
45.8
|
$ |
965
|
4.6
|
|||||||||||||||
Household
Cleaning
|
9,260
|
29.5
|
10,289
|
32.9
|
(1,029 | ) | (10.0 | ) | ||||||||||||||||
Personal
Care
|
2,129
|
36.0
|
2,352
|
33.4
|
(223 | ) | (9.5 | ) | ||||||||||||||||
$ |
33,550
|
38.4
|
$ |
33,837
|
40.0
|
$ | (287 | ) | (0.8 | ) |
Contribution
margin, defined as gross profit less advertising and promotional expenses,
decreased $287,000, or 0.8%, for 2007 versus the comparable period in
2006. The contribution margin decrease was a result of the increase
in sales and gross profit as previously discussed, offset by a $1.6 million,
or
a 16.6% increase in advertising and promotional spending. The
increased advertising and promotional spending was primarily attributable to
support behind the launches of Murine Earigate and Comet Mildew
SprayGel.
-26-
Over-the-Counter
Healthcare Segment
Contribution
margin for the Over-the-Counter Healthcare segment increased by $1.0 million,
or
4.6%, for 2007 versus the comparable period in 2006. The contribution
margin increase was a result of the increase in sales and gross profit as
previously discussed, partially offset by a $1.1 million, or a 15.5% increase
in
advertising and promotional spending. The increase in advertising and
promotional spending was primarily a result of television media support behind
the launch of Murine Earigate.
Household
Cleaning Segment
Contribution
margin for the Household Cleaning segment decreased by $1.0 million, or 10.0%,
for 2007 versus the comparable period in 2006. The contribution
margin decrease was a result of a decrease in gross profit as previously
discussed and $600,000, or a 27.4% increase of advertising and promotional
spending. The increase was principally a result of increased
television media support behind Comet Mildew SprayGel.
Personal
Care Segment
Contribution
margin for the Personal Care segment decreased $223,000, or 9.5%, for 2007
versus the comparable period in 2006. The contribution margin
decrease was primarily a result of the sales and gross profit decrease
previously discussed.
General
and Administrative
General
and administrative expenses were $10.2 million for 2007 versus $7.3 million
for
2006. The increase was primarily related to higher legal costs
associated with the OraSure arbitration and four intellectual property legal
actions initiated by the Company associated with The Doctor’s® NightGuardTM dental
protector.
Depreciation
and Amortization
Depreciation
and amortization expense was $2.8 million for 2007 versus $2.4 million for
2006. The increase in amortization of intangible assets is related to
the Wartner acquisition, which was partially offset by a slight reduction in
depreciation expense.
Interest
Expense
Net
interest expense was $9.6 million for 2007 versus $9.7 million for
2006. The reduction in interest expenses was the result of a lower
level of indebtedness partially offset by higher interest rates on our variable
rate indebtedness. The average cost of funds increased from 7.9% for
2006 to 8.7% for 2007.
Income
Taxes
The
income tax provision for 2007 was $4.2 million, with an effective rate of 38.0%,
compared to $5.6 million, with an effective rate of 39.1% for
2006. During the fiscal year ended March 31, 2007, the Company
implemented various initiatives to obtain operational, as well as tax,
efficiencies.
-27-
|
Six
Month Period Ended September 30, 2007 compared to
the
|
|
Six
Month Period Ended September 30,
2006
|
Revenues
2007
Revenues
|
%
|
2006
Revenues
|
%
|
Increase
(Decrease)
|
%
|
|||||||||||||||||||
OTC
Healthcare
|
$ |
92,429
|
55.7
|
$ |
85,853
|
53.5
|
$ |
6,576
|
7.7
|
|||||||||||||||
Household
Cleaning
|
61,309
|
36.9
|
61,344
|
38.2
|
(35 | ) | (0.1 | ) | ||||||||||||||||
Personal
Care
|
12,210
|
7.4
|
13,277
|
8.3
|
(1,067
|
) | (8.0 | ) | ||||||||||||||||
$ |
165,948
|
100.0
|
$ |
160,474
|
100.0
|
$ |
5,474
|
3.4
|
Revenues
for the six month period ended September 30, 2007 increased $5.5 million, or
3.4%, versus the comparable period in 2006, primarily as a result of the
acquisition of the Wartner brand in September of 2006. Excluding the
impact of the Wartner acquisition, revenues were essentially flat versus the
comparable period in 2006. Revenues to customers outside of North
America, which represented 4.3% of total revenues, were flat in 2007 versus
the
comparable period in 2006.
During
the period the Company increased its allowance for returns by $1.1 million
in
connection with the voluntary withdrawal from the marketplace of two medicated
pediatric cough and cold products marketed under the Little Remedies
brand. This action was part of an industry wide voluntary withdrawal
of these items pending the final results of an FDA safety and efficacy
review. Excluding the impact of the withdrawal, total revenues for
the Company would have been $167.0 million, or 4.0% greater than the same period
last year and up 0.7% excluding the Wartner acquisition.
Over-the-Counter
Healthcare Segment
Revenues
of the Over-the-Counter Healthcare segment increased by $6.6 million, or 7.7%,
for 2007 versus the comparable period in 2006. The revenue increases
were primarily due to the acquisition of the Wartner brand in September 2006
and
the launch of Murine EarigateTM, a new
product
that helps prevent earwax build-up with its patented reverse spray
technology. Excluding the impact of the Wartner acquisition, revenues
increased by 1.4% for the period. Revenue increases from Murine
EarigateTM,
Dermoplast and New Skin were partially offset by decreases in Chloraseptic,
Clear eyes®,
The Doctor’s® and Little Remedies. New Skin’s revenue increased as a
result of higher consumption and market share gains in the liquid bandage
category. Dermoplast’s revenue increased as a result of strong
shipments of the institutional size to wholesale
distributors. Chloraseptic’s revenue decreased as a result of weaker
consumption and lower shipments to the trade in advance of the flu
season. The Clear eyes revenue declined as a result of
comparisons to strong pipeline sales of new items during the six month period
ended September 30, 2006. The Doctor’s® revenue decreased as a result
of increased competition in the bruxism category. Little Remedies’
revenue declined due to a $1.1 million
increase in the allowance for returns in connection with the voluntary
withdrawal from the marketplace of Little Remedies medicated pediatric cough
and
cold products. Compound W®
revenues
were down
slightly primarily due to softer trends in the cryogenic sub-segment of the
wart
removal category.
Household
Cleaning Segment
Revenues
of the Household Cleaning segment were essentially flat during the period versus
the comparable period in 2006. Revenues of the Comet® brand were
flat
for the period and declines in Spic and Span were offset by increased revenue
from Chore Boy. Revenue of Comet Mildew SprayGel, which launched in
the last quarter of fiscal 2007, was offset by weaker factory sales of
Comet powder and bathroom sprays. Comet was negatively
affected by inventory reductions taken at a key mass merchandiser customer
while
bathroom sprays reflect declining consumption trends. The decline in
Spic and Span’s revenue was a result weaker consumption and in line with overall
declines in the all purpose cleaning category. Chore Boy’s revenue
increases were a result of strong shipments to small grocery wholesale accounts;
however, Chore Boy’s consumption declined during the period.
-28-
Personal
Care Segment
Revenues
of the Personal Care segment declined $1.1 million or 8.0% for 2007 versus
the
comparable period in 2006. All major brands in this segment, except
for Prell, experienced revenue declines during the period. The
decrease in revenues of Cutex®
and
Denorex® were
a result of declining consumption. Prell’s revenue increased
for the period primarily due to improved consumption.
Gross
Profit
2007
Gross
Profit
|
%
|
2006
Gross
Profit
|
%
|
Increase
(Decrease)
|
%
|
|||||||||||||||||||
OTC
Healthcare
|
$ |
57,355
|
62.1
|
53,455
|
62.3
|
$ |
3,900
|
7.3
|
||||||||||||||||
Household
Cleaning
|
23,329
|
38.1
|
24,249
|
39.5
|
(920 | ) | (3.8 | ) | ||||||||||||||||
Personal
Care
|
5,172
|
42.4
|
5,186
|
39.1
|
(14 | ) | (0.3 | ) | ||||||||||||||||
$ |
85,856
|
51.7
|
$ |
82,890
|
51.1
|
$ |
2,966
|
3.6
|
Gross
profit for 2007 increased by $3.0 million, or 3.6%, versus the comparable period
in 2006. As a percent of total revenue, gross profit increased from
51.1% in 2006 to 51.7% during 2007. The increase in gross profit as a
percent of revenues was a result of favorable sales mix to higher margin
products partially offset by a $1.1 million increase in the allowance for
returns in connection with the voluntary withdrawal of the two Little Remedies
medicated products discussed above and related obsolescence charges of
$800,000.
Over-the-Counter
Healthcare Segment
Gross
profit of the Over-the-Counter Healthcare segment increased $3.9 million, or
7.3%, for 2007 versus the comparable period in 2006. As a percent of
OTC revenue, gross profit decreased from 62.3% for 2006 to 62.1% during
2007. The decrease in gross profit as a percent of revenues was a
result of a $1.1 million increase in the allowance for returns in connection
with the voluntary withdrawal of Little Remedies medicated product discussed
above and related obsolescence charges of $800,000.
Household
Cleaning Segment
Gross
profit of the Household Cleaning segment decreased by $920,000, or 3.8%, for
2007 versus the comparable period in 2006. As a percent of household
cleaning revenue, gross profit decreased from 39.5% for 2006 to 38.1% during
2007. The decrease in gross profit percentage was primarily a result
of higher product costs partially offset by lower distribution
costs. The product cost increases were a result of higher raw
material costs.
Personal
Care Segment
Gross
profit of the Personal Care segment was flat for 2007 versus the comparable
period in 2006. As a percent of personal care revenue, gross profit
increased from 39.1% for 2006 to 42.4% during 2007. The increase in
gross profit percentage was primarily a result of favorable product mix, lower
returns and a reduction in promotional pricing allowances.
Contribution
Margin
2007
Contribution
Margin
|
%
|
2006
Contribution
Margin
|
%
|
Increase
(Decrease)
|
%
|
|||||||||||||||||||
OTC
Healthcare
|
$ |
43,320
|
46.9
|
$ |
40,972
|
47.7
|
$ |
2,348
|
5.7
|
|||||||||||||||
Household
Cleaning
|
19,126
|
31.2
|
20,539
|
32.5
|
(1,413 | ) | (6.9 | ) | ||||||||||||||||
Personal
Care
|
4,607
|
37.7
|
4,522
|
34.1
|
85
|
1.9
|
||||||||||||||||||
$ |
67,053
|
40.4
|
$ |
66,033
|
41.1
|
$ |
1,020
|
1.5
|
Contribution
margin, defined as gross profit less advertising and promotional expenses,
increased $1.0 million, or 1.5%, for 2007 versus the comparable period in
2006. The contribution margin increase was a result of the
-29-
increase
in sales and gross profit as previously discussed, offset by a $1.9 million
or
11.5% increase in advertising and promotional spending. The increase
in advertising and promotional spending was primarily attributable to support
behind the launches of Murine Earigate and Comet Mildew SprayGel, and increased
television media support of The Doctor’s® NightGuardTM dental
protector.
Over-the-Counter
Healthcare Segment
Contribution
margin for the Over-the-Counter Healthcare segment increased by $2.3 million,
or
5.7%, for 2007 versus the comparable period in 2006. The contribution
margin increase was a result of the increase in sales and gross profit as
previously discussed, partially offset by a $1.6 million, or a 5.7% increase
in
advertising and promotional spending. The increase in advertising and
promotional spending was primarily a result of television media support behind
the launch of Murine Earigate and The Doctor’s® NightGuardTM dental
protector.
Household
Cleaning Segment
Contribution
margin for the Household Cleaning segment decreased by $1.4 million, or 6.9%,
for 2007 versus the comparable period in 2006. The contribution
margin decrease was a result of flat sales and a decrease in gross profit as
previously discussed and $500,000, or a 13.3% increase of advertising and
promotional spending. The increase was a result of an increase in
television media support behind Comet Mildew SprayGel.
Personal
Care Segment
Contribution
margin for the Personal Care segment increased $85,000, or 1.9%, for 2007 versus
the comparable period in 2006. The contribution margin increase was
primarily the result of the sales and gross profit decrease previously discussed
offset by a $99,000 reduction in advertising and promotional
spending.
General
and Administrative
General
and administrative expenses were $17.8 million for 2007 versus $13.7 million
for
2006. The increase was primarily related to higher legal and
stock-based compensation costs.
Depreciation
and Amortization
Depreciation
and amortization expense was $5.5 million for 2007 versus $4.8 million for
2006. The increase in amortization of intangible assets is related to
the Wartner acquisition, which was partially offset by a slight reduction in
depreciation expense.
Interest
Expense
Net
interest expense was $19.3 million for 2007 versus $19.5 million for
2006. The reduction in interest expenses was the result of a lower
level of indebtedness partially offset by higher interest rates on our variable
rate indebtedness. The average cost of funds increased from 7.9% for
2006 to 8.7% for 2007.
Income
Taxes
The
income tax provision for 2007 was $9.3 million, with an effective rate of 38.0%,
compared to $10.9 million, with an effective rate of 39.1% for
2006. During the fiscal year ended March 31, 2007, the Company
implemented various initiatives to obtain operational, as well as tax,
efficiencies.
-30-
Liquidity
and Capital Resources
Liquidity
We
have
financed and expect to continue to finance our operations with a combination
of
internally generated funds and borrowings. Pursuant to the terms of
the Senior Credit Facility, we may borrow an additional $200.0 million under
our
Tranche B Term Loan Facility and up to a maximum of $60.0 million under our
Revolving Credit Facility. Our principal uses of cash are for
operating expenses, debt service, acquisitions, working capital and capital
expenditures.
Six
Months Ended September 30
|
||||||||
(In
thousands)
|
2007
|
2006
|
||||||
Cash
provided by (used for):
|
||||||||
Operating
Activities
|
$ |
21,492
|
$ |
42,734
|
||||
Investing
Activities
|
(210 | ) | (31,555 | ) | ||||
Financing
Activities
|
(26,241 | ) | (8,871 | ) |
Operating
Activities
Net
cash
provided by operating activities was $21.5 million for 2007 compared to $42.7
million 2006. The $21.2 million decrease in net cash provided by
operating activities was primarily the result of the following:
·
|
A
decrease of net income of $1.9 million from $17.0 million for 2006
to
$15.1 million for 2007, and
|
·
|
An
increase in the components of working capital caused primarily by
an
increase in accounts receivable resulting from the timing of sales
in
advance of the cough/cold season, as well as an increase in accrued
liabilities resulting from the recognition of costs associated with
the
voluntary withdrawal from the marketplace of two medicated pediatric
cough and cold products marketed under the Little Remedies
brand.
|
Investing
Activities
Net
cash
used for investing activities was $210,000 for 2007 compared to $31.6 million
for 2006. The net cash used for investing activities for 2007 was
primarily for the acquisition of machinery, computers and office equipment,
while for 2006, net cash was used primarily for the acquisition of Wartner
USA
B.V.
Financing
Activities
Net
cash
used for financing activities was $26.2 million for 2007 compared to $8.9
million for 2006. During 2007, the Company repaid $24.5 million of
indebtedness in excess of normal maturities with cash generated from
operations. This reduced our outstanding indebtedness to $437.1
million from $463.4 million at March 31, 2007. During 2006, the
Company repaid the remaining $7.0 million indebtedness related to our Revolving
Credit Facility which was drawn upon in connection with the November 2005
acquisition of Dental Concepts LLC.
The
Company’s cash flow from operations is normally expected to exceed net income
due to the substantial non-cash charges related to depreciation and amortization
of intangibles, increases in deferred income tax liabilities resulting from
differences in the amortization of intangible assets and goodwill for income
tax
and financial reporting purposes, the amortization of certain deferred financing
costs and stock-based compensation.
Capital
Resources
As
of
September 30, 2007, we had an aggregate of $437.1 million of outstanding
indebtedness, which consisted of the following:
·
|
$311.1
million of borrowings under the Tranche B Term Loan Facility,
and
|
·
|
$126.0
million of 9.25% Senior Subordinated Notes due
2012.
|
-31-
We
had
$60.0 million of borrowing capacity available under the Revolving Credit
Facility at September 30, 2007, as well as $200.0 million available under the
Tranche B Term Loan Facility.
All
loans
under the Senior Credit Facility bear interest at floating rates, based on
either the prime rate, or at our option, the LIBOR rate, plus an applicable
margin. As of September 30, 2007, an aggregate of $311.1 million was
outstanding under the Senior Credit Facility at a weighted average interest
rate
of 7.74%.
In
June
2004, we purchased a 5% interest rate cap agreement with a notional amount
of
$20.0 million which expired in June 2006. In March 2005, we purchased
interest rate cap agreements that became effective August 30, 2005, with a
total
notional amount of $180.0 million and LIBOR cap rates ranging from 3.25% to
3.75%. On May 31, 2006, an interest rate cap agreement with a
notional amount of $50.0 million and a 3.25% cap rate
expired. Additionally, an interest rate cap agreement with a notional
amount of $80.0 million and a 3.50% cap rate expired on May 30,
2007. The remaining agreement, with a notional amount of $50.0
million and a cap rate of 3.75%, terminates on May 30, 2008. The fair
value of the interest rate cap agreement was $486,000 at September 30,
2007.
The
Tranche B Term Loan Facility matures in October 2011. We must make
quarterly principal payments on the Tranche B Term Loan Facility equal to
$887,500, representing 0.25% of the initial principal amount of the term
loan. The Revolving Credit Facility matures and the commitments
relating to the Revolving Credit Facility terminate in April 2009.
The
Senior Credit Facility contains various financial covenants, including
provisions that require us to maintain certain leverage ratios, interest
coverage ratios and fixed charge coverage ratios. In addition, the
Senior Credit Facility, as well as the Indenture governing the Senior
Subordinated Notes, contain provisions that accelerate our indebtedness on
certain changes in control and restrict us from undertaking specified corporate
actions, including asset dispositions, acquisitions, payment of dividends and
other specified payments, repurchasing the Company’s equity securities in the
public markets, incurrence of indebtedness, creation of liens, making loans
and
investments and transactions with affiliates. Specifically, we
must:
·
|
Have
a leverage ratio of less than 4.5 to 1.0 for the quarter ended September
30, 2007, decreasing over time to 3.75 to 1.0 for the quarter ending
September 30, 2010, and remaining level
thereafter,
|
·
|
Have
an interest coverage ratio of greater than 2.75 to 1.0 for the quarter
ended September 30, 2007, increasing over time to 3.25 to 1.0 for
the
quarter ending March 31, 2010, and
|
·
|
Have
a fixed charge coverage ratio of greater than 1.5 to 1.0 for the
quarter
ended September 30, 2007, and for each quarter thereafter until the
quarter ending March 31, 2011.
|
At
September 30, 2007, we were in compliance with the applicable financial and
restrictive covenants under the Senior Credit Facility and the Indenture
governing the Senior Subordinated Notes.
Our
principal sources of funds are anticipated to be cash flows from operating
activities and available borrowings under the Senior Credit
Facility. We believe that these funds will provide us with sufficient
liquidity and capital resources for us to meet our current and future financial
obligations, as well as to provide funds for working capital, capital
expenditures and other needs for at least the next 12 months. As part
of our growth strategy, we regularly review acquisition opportunities and other
potential strategic transactions, which may require additional debt or equity
financing. If additional financing is required, there are no
assurances that it will be available, or if available, that it can be obtained
on terms favorable to us or on a basis that is not dilutive to our
stockholders.
-32-
Off-Balance
Sheet Arrangements
We
do not
have any off-balance sheet arrangements or financing activities with
special-purpose entities.
Inflation
Inflationary
factors such as increases in the costs of raw materials, packaging materials,
purchased product and overhead may adversely affect our operating
results. Although we do not believe that inflation has had a material
impact on our financial condition or results from operations for the periods
referred to above, a high rate of inflation in the future could have a material
adverse effect on our business, financial condition or results from
operations. The current volatility of the crude oil markets will
continue to impact, at times favorably and at times unfavorably, our
transportation costs, as well as, certain petroleum based raw materials and
packaging materials. Although the Company takes efforts to minimize
the impact of inflationary factors, including raising prices to our customers,
a
sustained rate of pricing increases associated with crude oil supplies may
have
an adverse effect on our operating results.
Seasonality
The
first
quarter of our fiscal year typically has the lowest level of revenue due to
the
seasonal nature of certain of our brands relative to the summer and winter
months. In addition, the first quarter is the least profitable
quarter due to the increased advertising and promotional spending to support
those brands with a summer selling season, such as Compound W, Wartner, Cutex
and New Skin. The Company’s advertising and promotional campaign in
the third quarter influence sales in the fourth quarter winter
months. Additionally, the fourth quarter typically has the lowest
level of advertising and promotional spending as a percent of
revenue.
-33-
Critical
Accounting Policies and Estimates
The
Company’s significant accounting policies are described in the notes to the
unaudited financial statements included elsewhere in this Quarterly Report
on
Form 10-Q, as well as in our Annual Report on Form 10-K for the year ended
March
31, 2007. While all significant accounting policies are important to our
consolidated financial statements, certain of these policies may be viewed
as
being critical. Such policies are those that are both most important to
the portrayal of our financial condition and results from operations and require
our most difficult, subjective and complex estimates and assumptions that affect
the reported amounts of assets, liabilities, revenues, expenses or the related
disclosure of contingent assets and liabilities. These estimates are based
upon our historical experience and on various other assumptions that we believe
to be reasonable under the circumstances. Actual results may differ
materially from these estimates under different conditions. The most
critical accounting policies are as follows:
Revenue
Recognition
We
comply
with the provisions of Securities and Exchange Commission Staff Accounting
Bulletin 104 “Revenue Recognition,” which states that revenue should be
recognized when the following revenue recognition criteria are met: (1)
persuasive evidence of an arrangement exists; (2) the product has been shipped
and the customer takes ownership and assumes the risk of loss; (3) the selling
price is fixed or determinable; and (4) collection of the resulting receivable
is reasonably assured. We have determined that the transfer of risk
of loss occurs when product is received by the customer, and, accordingly
recognize revenue at that time. Provision is made for estimated
discounts related to customer payment terms and estimated product returns at
the
time of sale based on our historical experience.
As
is
customary in the consumer products industry, we participate in the promotional
programs of our customers to enhance the sale of our products. The
cost of these promotional programs is recorded in accordance with Emerging
Issues Task Force 01-09, “Accounting for Consideration Given by a Vendor to
a Customer (Including a Reseller of the Vendor’s Products)” as either
advertising and promotional expenses or as a reduction of sales. Such
costs vary from period-to-period based on the actual number of units sold during
a finite period of time. We estimate the cost of such promotional
programs at their inception based on historical experience and current market
conditions and reduce sales by such estimates. These promotional
programs consist of direct to consumer incentives such as coupons and temporary
price reductions, as well as incentives to our customers, such as slotting
fees
and cooperative advertising. We do not provide incentives to
customers for the acquisition of product in excess of normal inventory
quantities since such incentives increase the potential for future returns,
as
well as reduce sales in the subsequent fiscal periods.
Estimates
of costs of promotional programs are based on (i) historical sales experience,
(ii) the current offering, (iii) forecasted data, (iv) current market
conditions, and (v) communication with customer purchasing/marketing
personnel. At the completion of the promotional program, the
estimated amounts are adjusted to actual results. While our
promotional expense for the year ended March 31, 2007 was $16.5 million, we
participated in 5,900 promotional campaigns, resulting in an average cost of
$2,800 per campaign. Of such amount, only 582 payments were in excess
of $5,000. We believe that the estimation methodologies
employed, combined with the nature of the promotional campaigns, makes the
likelihood remote that our obligation would be misstated by a material
amount. However, for illustrative purposes, had we underestimated the
promotional program rate by 10% for the three and six month periods ended
September 30, 2007, our sales and operating income would have been
adversely affected by approximately $529,00 and $993,000,
respectively.
We
also
periodically run coupon programs in Sunday newspaper inserts or as on-package
instant redeemable coupons. We utilize a national clearing house to
process coupons redeemed by customers. At the time a coupon is
distributed, a provision is made based upon historical redemption rates for
that
particular product, information provided as a result of the clearing house’s
experience with coupons of similar dollar value, the length of time the coupon
is valid, and the seasonality of the coupon drop, among other
factors. During the year ended March 31, 2007, we had 17 coupon
events. The amount recorded against revenues and accrued for these
events during the year was $2.7 million, of which $2.3 million was redeemed
during the year. During the six month period ended September 30,
2007, we had 16 coupon events. The amount recorded against revenues
and accrued for these events during the three and six month periods ended
September 30, 2007 was $602,000 and $1.1 million,
-34-
respectively. Redemptions
during the three and six month periods ended September 30, 2007 were $696,000
and $1.1 million, respectively.
Allowances
for Product Returns
Due
to
the nature of the consumer products industry, we are required to estimate
future product returns. Accordingly, we record an estimate of
product returns concurrent with the recording of sales. Such
estimates are made after analyzing (i) historical return rates, (ii) current
economic trends, (iii) changes in customer demand, (iv) product acceptance,
(v)
seasonality of our product offerings, and (vi) the impact of changes in
product formulation, packaging and advertising.
We
construct our returns analysis by looking at the previous year’s return history
for each brand. Subsequently, each month, we estimate our current
return rate based upon an average of the previous six months’ return rate and
review that calculated rate for reasonableness giving consideration to the
other
factors described above. Our historical return rate has been relatively
stable; for example, for the years ended March 31, 2007, 2006 and 2005, returns
represented 3.7%, 3.5%, and 3.6%, respectively, of gross sales. At
September 30, 2007 and March 31, 2007, the allowances for sales returns were
$2.1 million and $1.8 million, respectively.
While
we
utilize the methodology described above to estimate product returns, actual
results may differ materially from our estimates, causing our future financial
results to be adversely affected. Among the factors that could cause
a material change in the estimated return rate would be significant unexpected
returns with respect to a product or products that comprise a significant
portion of our revenues. Based upon the methodology described above
and our actual returns’ experience, management believes the likelihood of such a
material occurrence is remote. As noted, over the last three years,
our actual product return rate has stayed within a range of 3.5% to 3.7% of
gross sales. An increase of 0.1% in our estimated return rate as a
percentage of gross sales would have adversely affected our reported sales
and
operating income for the three and six month periods ended September 30,
2007 by approximately $102,000 and $193,000, respectively.
Allowances
for Obsolete and Damaged Inventory
We
value
our inventory at the lower of cost or market value. Accordingly, we
reduce our inventories for the diminution of value resulting from product
obsolescence, damage or other issues affecting marketability equal to the
difference between the cost of the inventory and its estimated market
value. Factors utilized in the determination of estimated market
value include (i) current sales data and historical return rates, (ii) estimates
of future demand, (iii) competitive pricing pressures, (iv) new product
introductions, (v) product expiration dates, and (vi) component and packaging
obsolescence.
Many
of
our products are subject to expiration dating. As a general rule our
customers will not accept goods with expiration dating of less than 12 months
from the date of delivery. To monitor this risk, management utilizes
a detailed compilation of inventory with expiration dating between zero and
15
months and reserves for 100% of the cost of any item with expiration dating
of
12 months or less. At September 30, 2007 and March 31, 2007, the
allowance for obsolete and slow moving inventory represented 4.4% and 5.8%,
respectively, of total inventory. Inventory obsolescence costs
charged to operations for the three and six month periods ended September 30,
2007 were $872,000 and $583,000, respectively. During the three month
period ended June 30, 2007, the Company recorded a credit of $289,000 to
operations for obsolescence due to the settlement of a claim from a
vendor. A 1.0% increase in our allowance for obsolescence at
September 30, 2007 would have adversely affected our reported operating income
for the three and six month periods ended September 30, 2007 by approximately
$291,000.
Allowance
for Doubtful Accounts
In
the
ordinary course of business, we grant non-interest bearing trade credit to
our customers on normal credit terms. We maintain an allowance for
doubtful accounts receivable which is based upon our historical collection
experience and expected collectibility of the accounts receivable. In
an effort to reduce our credit risk, we (i) establish credit limits for all
of
our customer relationships, (ii) perform ongoing credit evaluations of our
customers’ financial condition, (iii) monitor the payment history and aging of
our customers’ receivables, and (iv) monitor open orders against an individual
customer’s outstanding receivable balance.
-35-
We
establish specific reserves for those accounts which file for bankruptcy, have
no payment activity for 180 days or have reported major negative changes to
their financial condition. The allowance for bad debts at September
30, 2007 and March 31, 2007 amounted to 0.12% and 0.10%, respectively, of
accounts receivable. For the three and six months ended September 30,
2007 we recorded bad debt expense of $15,000 and $99,000, respectively, while
during the three and six month periods ended September 30, 2006 we recorded
bad
debt recoveries of $67,000 and $12,000, respectively.
While
management believes that it is diligent in its evaluation of the adequacy of
the
allowance for doubtful accounts, an unexpected event, such as the bankruptcy
filing of a major customer, could have an adverse effect on our future financial
results. A 0.1% increase in our bad debt expense as a percentage of
net sales would have resulted in a decrease in operating income for the three
and six month periods ended September 30, 2007 of approximately $87,000 and
$165,000, respectively.
Valuation
of Intangible Assets and Goodwill
Goodwill
and intangible assets amounted to $960.8 million and $968.1 million at September
30, 2007 and March 31, 2007, respectively. As of September 30,
2007, goodwill and intangible assets were apportioned among our three operating
segments as follows:
Over-the-Counter
Healthcare
|
Household
Cleaning
|
Personal
Care
|
Consolidated
|
|||||||||||||
Goodwill
|
$ |
233,615
|
$ |
72,549
|
$ |
2,751
|
$ |
308,915
|
||||||||
Intangible
assets
|
||||||||||||||||
Indefinite
lived
|
374,070
|
170,893
|
--
|
544,963
|
||||||||||||
Finite
lived
|
90,986
|
15
|
15,939
|
106,940
|
||||||||||||
465,056
|
170,908
|
15,939
|
651,903
|
|||||||||||||
$ |
698,671
|
$ |
243,457
|
$ |
18,690
|
$ |
960,818
|
Our
Clear
Eyes, New-Skin, Chloraseptic, Compound W and Wartner brands comprise the
majority of the value of the intangible assets within the Over-The-Counter
Healthcare segment. The Comet, Spic and Span and Chore Boy brands
comprise substantially all of the intangible asset value within the Household
Cleaning segment. Denorex, Cutex and Prell comprised substantially all of
the intangible asset value within the Personal Care segment.
Goodwill
and intangible assets comprise substantially all of our
assets. Goodwill represents the excess of the purchase price over the
fair value of assets acquired and liabilities assumed in a purchase business
combination. Intangible assets generally represent our trademarks,
brand names and patents. When we acquire a brand, we are required to
make judgments regarding the value assigned to the associated intangible
assets, as well as their respective useful lives. Management
considers many factors, both prior to and after, the acquisition of an
intangible asset in determining the value, as well as the useful life, assigned
to each intangible asset that the Company acquires or continues to own and
promote. The most significant factors are:
·
|
Brand
History
|
A
brand
that has been in existence for a long period of time (e.g., 25, 50 or
100 years) generally warrants a higher valuation and longer life (sometimes
indefinite) than a brand that has been in existence for a very short period
of
time. A brand that has been in existence for an extended period of
time generally has been the subject of considerable investment by its previous
owner(s) to support product innovation and advertising and
promotion.
-36-
·
|
Market
Position
|
Consumer
products that rank number one or two in their respective market generally have
greater name recognition and are known as quality product offerings, which
warrant a higher valuation and longer life than products that lag in the
marketplace.
·
|
Recent
and Projected Sales Growth
|
Recent
sales results present a snapshot as to how the brand has performed in the most
recent time periods and represent another factor in the determination of brand
value. In addition, projected sales growth provides information about
the strength and potential longevity of the brand. A brand that has
both strong current and projected sales generally warrants a higher valuation
and a longer life than a brand that has weak or declining
sales. Similarly, consideration is given to the potential investment,
in the form of advertising and promotion, that is required to reinvigorate
a
brand that has fallen from favor.
·
|
History
of and Potential for Product
Extensions
|
Consideration
also is given to the product innovation that has occurred during the brand’s
history and the potential for continued product innovation that will determine
the brand’s future. Brands that can be continually enhanced by new
product offerings generally warrant a higher valuation and longer life than
a
brand that has always “followed the leader”.
After
consideration of the factors described above, as well as current economic
conditions and changing consumer behavior, management prepares a determination
of the intangible’s value and useful life based on its analysis of the
requirements of Statements No. 141 and No. 142. Under Statement No.
142, goodwill and indefinite-lived intangible assets are no longer amortized,
but must be tested for impairment at least annually. Intangible
assets with finite lives are amortized over their respective estimated useful
lives and must also be tested for impairment.
On
an
annual basis, or more frequently if conditions indicate that the carrying value
of the asset may not be recovered, management performs a review of both the
values and useful lives assigned to goodwill and intangible assets and tests
for
impairment.
Finite-Lived
Intangible Assets
As
mentioned above, management performs an annual review or more frequently if
necessary, to ascertain the impact of events and circumstances on the estimated
useful lives and carrying values of our trademarks and trade
names. In connection with this analysis, management:
·
|
Reviews
period-to-period sales and profitability by
brand,
|
·
|
Analyzes
industry trends and projects brand growth
rates,
|
·
|
Prepares
annual sales forecasts,
|
·
|
Evaluates
advertising effectiveness,
|
·
|
Analyzes
gross margins,
|
·
|
Reviews
contractual benefits or
limitations,
|
·
|
Monitors
competitors’ advertising spend and product
innovation,
|
·
|
Prepares
projections to measure brand viability over the estimated useful
life of
the intangible asset, and
|
·
|
Considers
the regulatory environment, as well as industry
litigation.
|
Should
analysis of any of the aforementioned factors warrant a change in the estimated
useful life of the intangible asset, management will reduce the estimated useful
life and amortize the carrying value prospectively over the shorter remaining
useful life. Management’s projections are utilized to assimilate all
of the facts, circumstances and expectations related to the trademark or trade
name and estimate the cash flows over its useful life. In the event
that the long-term projections indicate that the carrying value is in excess
of
the undiscounted cash flows expected to result from the use of the intangible
assets, management is required to record an impairment charge. Once
that analysis is completed, a discount rate is applied to the cash flows to
estimate fair value. The impairment charge is measured as the excess
of the carrying amount of the intangible asset over fair
-37-
value
as
calculated using the discounted cash flow analysis. Future events,
such as competition, technological advances and reductions in advertising
support for our trademarks and trade names could cause subsequent evaluations
to
utilize different assumptions.
Indefinite-Lived
Intangible Assets
In
a
manner similar to finite-lived intangible assets, on an annual basis, or more
frequently if necessary, management analyzes current events and circumstances
to
determine whether the indefinite life classification for a trademark or trade
name continues to be valid. Should circumstance warrant a finite
life, the carrying value of the intangible asset would then be amortized
prospectively over the estimated remaining useful life.
In
connection with this analysis, management also tests the indefinite-lived
intangible assets for impairment by comparing the carrying value of the
intangible asset to its estimated fair value. Since quoted market
prices are seldom available for trademarks and trade names such as ours, we
utilize present value techniques to estimate fair value. Accordingly,
management’s projections are utilized to assimilate all of the facts,
circumstances and expectations related to the trademark or trade name and
estimate the cash flows over its useful life. In performing this
analysis, management considers the same types of information as listed above
in
regards to finite-lived intangible assets. Once that analysis is
completed, a discount rate is applied to the cash flows to estimate fair
value. Future events, such as competition, technological advances and
reductions in advertising support for our trademarks and trade names could
cause
subsequent evaluations to utilize different assumptions.
Goodwill
As
part
of its annual test for impairment of goodwill, management estimates the
discounted cash flows of each reporting unit, which is at the brand level,
and
one level below the operating segment level, to estimate their respective fair
values. In performing this analysis, management considers the same
types of information as listed above in regards to finite-lived intangible
assets. In the event that the carrying amount of the reporting unit
exceeds the fair value, management would then be required to allocate the
estimated fair value of the assets and liabilities of the reporting unit as
if
the unit was acquired in a business combination, thereby revaluing the carrying
amount of goodwill. In a manner similar to indefinite-lived assets,
future events, such as competition, technological advances and reductions in
advertising support for our trademarks and trade names could cause subsequent
evaluations to utilize different assumptions.
In
estimating the value of trademarks and trade names, as well as goodwill, at
March 31, 2007, management applied a discount rate of 9.5%, the Company’s then
current weighted-average cost of funds, to the estimated cash flows; however
that rate, as well as future cash flows may be influenced by such factors,
including (i) changes in interest rates, (ii) rates of inflation, or (iii)
sales
or contribution margin reductions. In the event that the carrying
value exceeded the estimated fair value of either intangible assets or goodwill,
we would be required to recognize an impairment charge. Additionally,
continued decline of the fair value ascribed to an intangible asset or a
reporting unit caused by external factors may require future impairment
charges.
During
the three month period ended March 31, 2006, we recorded non-cash charges
related to the impairment of intangible assets and goodwill of the Personal
Care
segment of $7.4 million and $1.9 million, respectively, because the
carrying amounts of these “branded” assets exceeded their fair market
values primarily as a result of declining sales caused by product
competition. Should the related fair values of goodwill and
intangible assets continue to be adversely affected as a result of declining
sales or margins caused by competition, technological advances or reductions
in
advertising and promotional expenses, the Company may be required to record
additional impairment charges.
Stock-Based
Compensation
During
2006, we
adopted FASB Statement No. 123(R), “Share-Based Payment” (“Statement No.
123(R)”) with the initial grants of restricted stock and options to purchase
common stock to employees and directors in accordance with the provisions of
the
Plan. Statement No. 123(R) requires us to measure the cost of
services to be rendered based on the grant-date fair value of the equity
award. Compensation expense is to be recognized over the period which
an employee is required to provide service in exchange for the award, generally
referred to
-38-
as
the
requisite service period. Information utilized in the determination
of fair value includes the following:
·
|
Type
of instrument (i.e.: restricted shares vs. an option, warrant or
performance shares),
|
·
|
Strike
price of the instrument,
|
·
|
Market
price of the Company’s common stock on the date of
grant,
|
·
|
Discount
rates,
|
·
|
Duration
of the instrument, and
|
·
|
Volatility
of the Company’s common stock in the public
market.
|
Additionally,
management must estimate the expected attrition rate of the recipients to enable
it to estimate the amount of non-cash compensation expense to be recorded in
our
financial statements. While management uses diligent analysis to
estimate the respective variables, a change in assumptions or market conditions,
as well as changes in the anticipated attrition rates, could have a significant
impact on the future amounts recorded as non-cash compensation
expense. The Company recorded stock-based compensation costs of
$655,000 and $383,000 during the fiscal years ended March 31, 2007 and 2006,
respectively. During the three and six month periods ended September
30, 2007, the Company recorded stock-based compensation costs of $685,000 and
$1.1 million, respectively. During the three and six month periods
ended September 30, 2006, the Company recorded stock-based compensation costs
of
$233,000 and $224,000, respectively. The period-to-period decrease
resulted from the recording of a net stock-based compensation credit of $9,000
during the three month period ended June 30, 2006 due to the reversal of
stock-based compensation costs in the amount of $142,000 associated with the
departure of a former member of management.
Loss
Contingencies
Loss
contingencies are recorded as liabilities when it is probable that a liability
has been incurred and the amount of such loss is reasonable
estimable. Contingent losses are often resolved over longer periods
of time and involve many factors including:
·
|
Rules
and regulations promulgated by regulatory
agencies,
|
·
|
Sufficiency
of the evidence in support of our
position,
|
·
|
Anticipated
costs to support our position, and
|
·
|
Likelihood
of a positive outcome.
|
Recent
Accounting Pronouncements
In
February 2007, the FASB issued SFAS No. 159, “The Fair Value Option for
Financial Assets and Financial Liabilities - Including an amendment of FASB
Statement No. 115” (“Statement No. 159”). Statement No. 159 permits
companies to choose to measure certain financial instruments and certain other
items at fair value. Unrealized gains and losses on items for which
the fair value option has been elected will be recognized in earnings at each
subsequent reporting date. Statement No. 159 is effective for interim
financial statements issued during the fiscal year beginning after November
15,
2007. The Company is evaluating the impact that the adoption of
Statement No. 159 will have on its consolidated financial
statements.
In
September 2006, the FASB issued SFAS No. 157, “Fair Value Measurements”
(“Statement No. 157”) to address inconsistencies in the definition and
determination of fair value pursuant to generally accepted accounting principles
(“GAAP”). Statement No. 157 provides a single definition of fair
value, establishes a framework for measuring fair value in GAAP and expands
disclosures about fair value measurements in an effort to increase comparability
related to the recognition of market-based assets and liabilities and their
impact on earnings. Statement No. 157 is effective for interim
financial statements issued during the fiscal year beginning after November
15,
2007.
Management
has reviewed and continues to monitor the actions of the various financial
and
regulatory reporting agencies and is currently not aware of any other
pronouncement that could have a material impact on the
Company’s consolidated financial position, results of operations or cash
flows.
-39-
CAUTIONARY
STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This
Quarterly Report on Form 10-Q contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLR
Act”), including, without limitation, information within Management’s Discussion
and Analysis of Financial Condition and Results of Operations. The
following cautionary statements are being made pursuant to the provisions of
the
PSLR Act and with the intention of obtaining the benefits of the “safe harbor”
provisions of the PSLR Act. Although we believe that our expectations
are based on reasonable assumptions, actual results may differ materially from
those in our forward-looking statements.
Forward-looking
statements speak only as of the date of this Quarterly Report on Form 10-Q.
Except as required under federal securities laws and the rules and
regulations of the SEC, we do not have any intention to update any
forward-looking statements to reflect events or circumstances arising after the
date of this Quarterly Report on Form 10-Q, whether as a result of new
information, future events or otherwise.
Our
forward-looking statements generally can be identified by the use of words
or
phrases such as “believe,” “anticipate,” “expect,” “estimate,” “project,” “will
be,” “will continue,” “will likely result,” or other similar words and
phrases. Forward-looking statements and our plans and expectations
are subject to a number of risks and uncertainties that could cause actual
results to differ materially from those anticipated, and our business in general
is subject to such risks. As a result
of these
risks and uncertainties, readers are cautioned not to place undue reliance
on
forward-looking statements included in this Quarterly
Report on
Form 10-Q
or that may be made
elsewhere from time to time by, or on behalf of, us. All
forward-looking
statements attributable to us are expressly qualified by
these cautionary
statements. For more information, see “Risk Factors” contained
in Part I, Item 1A of our Annual Report on Form 10-K for the year ended March
31, 2007. In addition, our expectations or beliefs concerning future
events involve risks and uncertainties, including, without
limitation:
·
|
General
economic conditions affecting our products and their respective
markets,
|
·
|
The
high level of competition in our industry and
markets,
|
·
|
Our
dependence on a limited number of customers for a large portion of
our
sales,
|
·
|
Disruptions
in our distribution center,
|
·
|
Acquisitions
or other strategic transactions diverting managerial resources, or
incurrence of additional liabilities or integration problems associated
with such transactions,
|
·
|
Changing
consumer trends or pricing pressures which may cause us to lower
our
prices,
|
·
|
Increases
in supplier prices,
|
·
|
Increases
in transportation fees and fuel
charges,
|
·
|
Changes
in our senior management team,
|
·
|
Our
ability to protect our intellectual property
rights,
|
·
|
Our
dependency on the reputation of our brand
names,
|
·
|
Shortages
of supply of sourced goods or interruptions in the manufacturing
of our
products,
|
·
|
Our
level of debt, and ability to service our
debt,
|
·
|
Any
adverse judgment rendered in any pending litigation or
arbitration,
|
·
|
Our
ability to obtain additional financing,
and
|
·
|
The
restrictions imposed by our financing agreements on our
operations.
|
-40-
ITEM 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
We
are
exposed to changes in interest rates because our Senior Credit Facility is
variable rate debt. Interest rate changes, therefore, generally do not
affect the market value of our senior secured financing, but do impact the
amount of our interest payments and, therefore, our future earnings and cash
flows, assuming other factors are held constant. At September 30,
2007, we had variable rate debt of approximately $311.1 million related to
our
Tranche B term loan.
In
an
effort to protect the Company from the adverse impact that rising interest
rates
would have on our variable rate debt, we have entered into various interest
rate
cap agreements to hedge this exposure. In June 2004, we
purchased a 5% interest rate cap agreement with a notional amount of $20.0
million which terminated in June 2006. In March 2005, we purchased
interest rate cap agreements that became effective August 30, 2005, with a
total notional amount of $180.0 million and LIBOR cap rates ranging from 3.25%
to 3.75%. On May 31, 2006, an interest rate cap agreement with a
notional amount of $50.0 million and a 3.25% cap rate
expired. Additionally, an interest rate cap agreement with a notional
amount of $80.0 million and a 3.5% cap rate expired on May 31,
2007. The remaining agreement, with a notional amount of $50.0
million and a cap rate of 3.75% terminates on May 31, 2008.
Holding
other variables constant, including levels of indebtedness, a one percentage
point increase in interest rates on our variable rate debt would have an adverse
impact on pre-tax earnings and cash flows for fiscal 2008 of approximately
$3.1
million. However, given the protection afforded by the interest rate
cap agreements, the impact of a one percentage point increase would be limited
to $2.8 million. The fair value of the interest rate cap agreement
was $486,000 at September 30, 2007.
ITEM 4. | CONTROLS AND PROCEDURES |
Disclosure
Controls and Procedures
Changes
in Internal Control over Financial Reporting
There
have been no changes during the quarter ended September 30, 2007 in the
Company’s internal control over financial reporting that have materially
affected, or are reasonably likely to materially affect, the Company’s internal
control over financial reporting.
-41-
OTHER
INFORMATION
|
ITEM
1.
|
LEGAL
PROCEEDINGS
|
The
legal
proceedings in which we are involved have been disclosed previously in our
Annual Report on Form 10-K for the fiscal year ended March 31, 2007, our
Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2007 and
our
Current Report on Form 8-K filed with the SEC on October 24,
2007. The following disclosure contains recent developments in our
pending legal proceedings and should be read in conjunction with the legal
proceedings disclosure contained in Part I, Item 3 of our Annual Report on
Form
10-K for the fiscal year ended March 31, 2007, Part II, Item 1 of our Quarterly
Report on Form 10-Q for the fiscal quarter ended June 30, 2007 and our Current
Report on Form 8-K filed with the SEC on October 24, 2007.
Securities
Class Action Litigation
On
September 4, 2007, the United States District Court for the Southern District
of
New York issued an Order certifying a class consisting of all persons who
purchased the common stock of the Company pursuant to, or traceable to, the
Company’s initial public offering on or about February 9, 2005 through November
15, 2005 and were damaged thereby. The Company’s management continues
to believe that the remaining claims in the case are legally deficient and
that
it has meritorious defenses to the claims that remain. The Company
intends to vigorously defend against the claims remaining in the case; however,
the Company cannot reasonably estimate the potential range of loss, if
any.
OraSure
Technologies Arbitration
At
the
end of August 2007, the Company and OraSure Technologies, Inc. (“OraSure”)
participated in an arbitration hearing at which each party presented its
case to
the arbitration panel. On October 22, 2007, the Company received
notification from the arbitrators that they had issued a Partial Final Award
(the “Award”) in the pending arbitration with OraSure. The
arbitrators acknowledged that there was a technical breach of the non-compete
clause in the Distribution Agreement between the parties but OraSure’s proof of
damages was speculative and not supported by credible
evidence. Therefore, the arbitrators awarded nominal damages to
OraSure in the amount of One Dollar ($1.00). In addition, the
arbitrators awarded to OraSure counsel fees and arbitrator compensation in
an
amount to be determined pursuant to further proceedings. The Company
will vigorously contest the award of fees to OraSure as the Company believes
that OraSure should only be entitled to a modest award in light of the
arbitrators’ rejection of OraSure’s asserted damages and claims beyond the One
Dollar ($1.00) nominal award.
The
arbitration panel also dismissed with prejudice OraSure’s remaining claims for
breach of the Distribution Agreement, OraSure’s request for injunctive relief
and the Company’s counterclaims, respectively. Furthermore, the
arbitrators confirmed the Company's position that the Distribution Agreement
will terminate on December 31, 2007. The Company does not expect any
interruptions in supply of its Compound W Freeze Off® branded cryosurgical wart
remover as it transitions to a new supplier after December 31,
2007.
DenTek
Oral Care, Inc. Litigation
In
April
2007, the Company filed a lawsuit in the U.S. District Court in the Southern
District of New York against DenTek Oral Care, Inc. (“DenTek”) alleging (i)
infringement of intellectual property associated with The Doctor’s®
NightGuardTM
dental protector
which is used for the protection of teeth from
nighttime teeth grinding; and (ii) the violation of unfair competition and
consumer protection laws. On October 4, 2007, the Company filed a
Second Amended Complaint in which it named Kelly M. Kaplan, Raymond Duane and
C.D.S. Associates, Inc. as additional defendants in the action against DenTek
and added other claims to the previously filed complaint. Ms. Kaplan
and Mr. Duane were formerly employed by the Company and C.D.S. Associates,
Inc.
is a corporation controlled by Mr. Duane. In the Second Amended
Complaint, the Company has alleged patent, trademark and copyright infringement,
unfair competition, unjust enrichment, violation of New York’s Consumer
Protection Act, breach of contract, tortuous interference with contractual
and
business relations, civil conspiracy and trade secret
misappropriation. On October 19, 2007, the Company filed a motion for
preliminary injunction with the Court in which the Company has asked the Court
to enjoin the defendants from (i) continuing to improperly use the Company’s
trade secrets; (ii) continuing to breach any contractual agreements with the
Company; and (iii) marketing and selling any dental protector products or other
products in which Ray Duane or Kelly Kaplan has had any involvement or provided
any assistance to DenTek. A hearing date for the motion for
preliminary
-42-
injunction
has not yet been set by the Court. Discovery requests have been
served by the parties and discovery is ongoing.
In
addition to the matters described above, the Company is involved from time
to time in other routine legal matters and other claims incidental to its
business. The Company reviews outstanding claims and proceedings
internally and with external counsel as necessary to assess probability and
amount of potential loss. These assessments are re-evaluated at each
reporting period and as new information becomes available to determine whether
a
reserve should be established or if any existing reserve should be
adjusted. The actual cost of resolving a claim or proceeding
ultimately may be substantially different than the amount of the recorded
reserve. In addition, because it is not permissible under GAAP to
establish a litigation reserve until the loss is both probable and estimable,
in
some cases there may be insufficient time to establish a reserve prior to the
actual incurrence of the loss (upon verdict and judgment at trial, for example,
or in the case of a quickly negotiated settlement). The Company
believes the resolution of routine matters and other incidental claims, taking
into account reserves and insurance, will not have a material adverse effect
on
its business, financial condition or results from operations.
ITEM 1A. | RISK FACTORS |
There
have been no material changes to the risk factors previously disclosed in Part
I, Item 1A, of our Annual Report on Form 10-K for the year ended March 31,
2007,
which is incorporated herein by reference.
ITEM
2.
|
UNREGISTERED
SALES OF EQUITY SECURITIES AND USE OF
PROCEEDS
|
There
were no purchases of shares of the Company’s common stock during the quarter
ended September 30, 2007, by or on behalf of the Company or any “affiliated
purchaser,” as defined by Rule 10b-18(a)(3) of the Exchange Act.
ITEM
4.
|
SUBMISSION
OF MATTERS TO A VOTE OF SECURITY
HOLDERS
|
The
Company’s 2007 Annual Meeting of Stockholders was held on July 31, 2007 (the
“Annual Meeting). Proxies for the Annual Meeting were solicited in
accordance with Regulation 14 of the Exchange Act to elect directors to serve
until the 2008 Annual Meeting of Stockholders or until their earlier removal
or
resignation and to ratify the appointment of PricewaterhouseCoopers LLP as
the
independent registered public accounting firm for the fiscal year ending March
31, 2008. The following nominees were elected to the Company’s Board
of Directors to serve until the 2008 Annual Meeting of Stockholders or until
their respective successors have been elected and qualified, or until their
earlier death, resignation or retirement. The voting information for
each elected nominee
-43-
is
set
forth below:
For
|
Withheld
|
||||||
Mark Pettie |
47,678,543
|
428,426
|
|||||
L. Dick Buell |
47,813,986
|
292,983
|
|||||
John E. Byom |
47,723,268
|
383,701
|
|||||
Gary E. Costley |
47,783,333
|
323,636
|
|||||
David A. Donnini |
26,036,225
|
22,070,744
|
|||||
Ronald Gordon |
47,659,068
|
447,901
|
|||||
Vincent J. Hemmer |
47,609,448
|
497,521
|
|||||
Patrick Lonergan |
47,723,173
|
383,796
|
|||||
Peter C. Mann |
47,609,948
|
497,021
|
|||||
Raymond P. Silcock |
47,701,121
|
405,848
|
The
votes
for the ratification of the appointment of PricewaterhouseCoopers LLP as the
Company’s independent registered public accounting firm for the audit of the
Company’s financial statements for the fiscal year ending March 31, 2008 were as
follows:
For
|
Against
|
Withheld
|
|||||
47,598,174
|
506,149
|
2,646
|
|||||
ITEM 6. | EXHIBITS |
See
Exhibit Index immediately following signature page.
-44-
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
Prestige Brands Holdings, Inc. | |||
Registrant
|
|||
Date: | November 8, 2007 | By: /s/ PETER J. ANDERSON | |
Peter J. Anderson | |||
Chief Financial Officer | |||
(Principal Financial Officer and | |||
Duly Authorized Officer) | |||
-45-
Exhibit
Index
31.1
|
Certification
of Principal Executive Officer of Prestige Brands Holdings, Inc.
pursuant
to Rule 13a-14(a) of the Securities Exchange Act of 1934.
|
31.2
|
Certification
of Principal Financial Officer of Prestige Brands Holdings, Inc.
pursuant
to Rule 13a-14(a) of the Securities Exchange Act of 1934.
|
32.1
|
Certification
of Principal Executive Officer of Prestige Brands Holdings, Inc.
pursuant
to Rule 13a-14(b) and Section 1350 of Chapter 63 of Title 18 of the
United
States Code.
|
32.2
|
Certification
of Principal Financial Officer of Prestige Brands Holdings, Inc.
pursuant
to Rule 13a-14(b) and Section 1350 of Chapter 63 of Title 18 of the
United
States Code.
|
-46-